Reducing Recidivism in Alaska Throough Access to Extended-Release Injectable Naltrexone by Green, Jyll K.




Jyll K. Green, M.S.N. 
 
A Dissertation Submitted in Partial Fulfillment of the Requirements 
for the Degree of  
 








 APPROVED:   
Lisa Jackson, D.N.P., Chair, Advisory Committee 
Thomas Hendrix, Ph.D., Committee Member  
Barbara Berner, Ed.D., Director  
 School of Nursing  
William H. Hogan, M.S.W., Dean 
 College of Health  
 Abstract 
The goal of this evidence-based project was to provide access to extended-release injectable 
naltrexone (XR-NTX) upon release from incarceration for individuals who had a self-identified 
substance or alcohol abuse history, and evaluate whether or not XR-NTX reduced recidivism in 
comparison with those who declined to use XR-NTX.  This project was completed in 
collaboration with Partners Reentry Center, located in Anchorage, Alaska, who collected and 
offered retrospective de-identified data for this project.  A total of 98 individuals with a self-
identified history of substance or alcohol abuse were offered XR-NTX through Partners Reentry 
Center from September 15, 2015 to September 15, 2016.  Of these, 52 were offered XR-NTX in 
the first six months of this evidenced-based quality improvement project.  Of those who accepted 
XR-NTX (n = 32), 62% remained in the community at the end of 12 months from project 
initiation.  Of those who declined XR-NTX (n = 20), 95% recidivated.  The results of this project 
demonstrate the benefit of using XR-NTX in released prisoners to reduce recidivism.  
Implications for use the of XR-NTX in Alaska Department of Corrections inmates and the 
general population who meet criteria for use should be evaluated. 
 Keywords:   extended-release injectable naltrexone, recidivism
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Reducing Recidivism in Alaska through Access to Extended-Release Injectable Naltrexone 
Chapter I: Overview of the Problem of Interest 
Nationwide, approximately 65% of individuals incarcerated in the criminal justice system 
are clinically addicted to drugs or alcohol.  Another 20% admit that drugs or alcohol were 
involved at the time of their crime (National Center on Addiction and Substance Abuse at 
Columbia University [CASA], 2010).  Alaska communities are suffering the consequences of 
crimes related to drugs and alcohol.  Of 25,385 crime victims in Alaska in 2010, 7,996 were 
attributed to drug or alcohol use (McDowell Group, Inc., 2012).  An estimated 37.1% of women 
in Alaska will be victims of sexual violence, of which 72.2% are a result of drug or alcohol use 
(Alaska State Troopers’ Alaska Bureau of Investigation Statewide Drug Enforcement Unit 
[SDEU], 2014).  According to the 2014 Annual Drug Report published by the SDEU, marijuana 
remains the number one reason for arrests directly related to drugs or alcohol (49%), followed by 
methamphetamines (16%), heroin (14%), alcohol (12%), prescription drugs (7%), and cocaine 
(2%).  Of particular concern, heroin addiction has doubled in the past decade and is now deemed 
an epidemic by the Centers for Disease Control and Prevention (CDC) (2015a).   
According to a 2012 report on the economic effects of drugs and alcohol in Alaska, in 
2010 there were 35,386 total arrests made, with 18,296 (52%) related to substance abuse.  Of 
these 18,296 arrestees, 1,529 were incarcerated at the cost of $56.7 million (McDowell Group, 
Inc., 2012).  Alaska ranks in the top 10 states in the nation for illicit drug or alcohol abuse, where 
13.3% of adults admitted illegal drug use in the prior month in comparison to the national 
average of 9.28% (SDEU, 2014).  Higher rates of substance abuse will lead to higher crime rates 
(National Institutes of Health [NIH], 2013).  Incarceration presents an opportunity to become 
free of drugs or alcohol.  However, many prisoners release from incarceration and return to 
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substance abuse.  A 2014 Bureau of Justice Statistics report found that 76.9% of drug offenders 
released in 2005 returned to prison by 2010 (Durose, Cooper, & Snyder, 2014); the greatest 
recidivism rate occurs within the first year after release (Gutierrez, 2015).   
The Alaska Department of Correction (ADOC) facilities are currently operating at 101% 
of capacity.  An 11% increase in incarcerated criminals is expected by 2018, primarily related to 
drug or alcohol abuse (Gutierrez, 2015).  It is clear that to reduce drug and alcohol related crime, 
recidivism, and the economic impact to the State of Alaska, efforts should focus on evaluation 
and treatment of substance misuse within the ADOC and as prisoners are released back into the 
community. 
Background 
Criminal recidivism is defined as the return to the criminal activity that results in 
rearrests, additional sanctions, or repeat incarceration (National Institute of Justice [NIJ], 2014).  
Recidivism can be viewed either as a failure of the individual for not rehabilitating themselves 
and choosing to be a good citizen or seen as a failure of the corrections system (Telidevara, 
2010).  The Alaska Judicial Council conducted a study in 2007 looking at recidivism rates for 
1,798 individuals who were sentenced during the year 1999 and found that 66% had recidivated 
within three years of release.  Further, recidivism within three years decreased to 63% in 2011 
when reformative programs were reinstated within the ADOC.  However, Alaska’s incarcerated 
population has continued to rise by 3% annually with projections as high as 12% over capacity 
by 2018 (Gutierrez, 2015).  Change is necessary to reduce recidivism and decrease the ADOC 
prisoner population.  
The 2015 Alaska Recidivism Reduction Plan (Gutierrez, 2015) is an evidence-based plan 
focusing on the most efficient ways to reduce recidivism.  Initiatives recommended by this plan 
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include collaboration within the Alaska therapeutic courts and community reentry partners, 
education and vocation programs, mental health treatment, housing needs, and substance abuse 
treatment.  There has been considerable community involvement throughout Alaska focusing on 
several of these initiatives.  
Therapeutic courts and reentry program.  Therapeutic courts are problem-solving 
courts comprised of a team of judicial staff working to ensure the future success of the defendant 
via behavioral health and substance abuse treatment in conjunction with careful monitoring by 
probation officers or guardians (Alaska Court System, n.d.; National Association of Drug Court 
Professionals [NADCP], n.d.).  The first therapeutic court was a drug court developed in 1989 in 
Miami-Dade, Florida.  As of 2012, there was a total of 2,734 drug courts throughout every state 
nationwide (NADCP, n.d.). 
 Therapeutic courts in Alaska.  Therapeutic courts within the Alaska Court System have 
been in operation since 1999.  In Alaska, there are 12 therapeutic courts comprised of wellness 
(substance abuse) and mental health courts, as well as several specialty therapeutic courts in 
Anchorage such as the Alaska for Veterans and Child in Need of Aid courts (Alaska Court 
System, n.d.; Gutierrez, 2015).  Participation in the therapeutic court system is voluntary; the 
defendant must plead guilty to the charges, and must have a diagnosed substance abuse and/or 
mental health disorder.  Participation is in lieu of jail time.  However, failure to complete the 
program results in usual sentencing for the crime (Alaska Court System, n.d.).  A 2012 report by 
the Alaska Judicial Council examined recidivism rates for 322 of over 500 Alaska Therapeutic 
Courts participants since the therapeutic courts’ inception in 1999.  A comparison of 
misdemeanants who graduated from the therapeutic court program with those who did not 
participate in a therapeutic court program identified a rearrest rate of 23% versus 36% and a 
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reconviction rate of 9% versus 25% within one-year post-release.  A comparison of felons who 
graduated from the therapeutic court program and felons who did not attend a therapeutic court 
program found a rearrests rate of 25% versus 36% and a reconviction rate of 12% versus 23% 
within one-year post-release (Alaska Judicial Council, 2012).  Given these outcomes, there is 
evidence that the therapeutic court system in Alaska is effective at reducing recidivism.   
 Reentry centers.  For substance abuse treatment to be beneficial, the treatment should be 
comprehensive and address all the needs of the individual including medical care, legal services, 
behavioral health services, social services such as food or housing needs, and vocational needs 
(National Institute on Drug Abuse [NIDA], 2012a).  Reentry Centers focus on identifying needs 
and providing resources for recently released prisoners and work with parole officers and the 
community to promote community success.  There are Reentry Centers located in Anchorage, 
Juneau, Matanuska-Susitna Valley, Fairbanks, and Dillingham (Gutierrez, 2015).  Partners 
Reentry Center (PRC) in Anchorage, Alaska, is a non-profit organization founded in 2013 with a 
goal to reduce recidivism by providing comprehensive services for recently released prisoners 
who are classified as high risk (Boots, 2013; Partners Reentry Center, n.d.).  PRC looks at the 
individual and assesses their basic needs for living as well as focusing on substance abuse 
disorders.   
 Recidivism risk assessment.  Recently released prisoners need a multifactorial approach 
to reducing the risk of recidivism and have successful reentry into their community.  Of those 
incarcerated today, 95% will be released at some point in time (James, 2015), with varying needs 
to successfully reenter their community.  The Level of Supervision Inventory-Revised (LSI-R) 
assessment is a 54 question quantitative tool to determine offender risk and best practices for 
intervention and treatment that improve post-release outcomes (Andrews & Bonta, 1995).  
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Labrecque, Smith, Lovins, and Latessa (2014) studied the theoretical benefit of using the LSI-R 
to predict risk of recidivism at initial screening and post interventions and found there was a 
positive correlation between LSI-R score and recidivism risk at both initial and subsequent 
scoring (r = .20 and .23, respectively, p < .01).  The level of services provided post release from 
incarceration need to correlate with LSI-R score.  A person with a high LSI-R score needs more 
services than a person with a low LSI-R score.  It is important to note that if an individual with a 
high LSI-R score is provided with a low level of services, and conversely if an individual with a 
low LSI-R score is provided with a high level of services (effectively mixing both high and low 
risk individuals), then recidivism increases (Marlowe, Festinger, Lee, Dugosh, & Benasutti, 
2006).  Thus, it is important to match the level of services based on actual risk and needs.   
  Education and vocational assistance.  Those convicted of a felony or misdemeanor in 
the State of Alaska have significant trouble gaining employment.  In Alaska, an estimated 51% 
of the adult working population has a conviction that may limit their ability to obtain 
employment (Gutierrez, 2015).  The Washington State Institute for Public Policy report showed 
that community-based education/training programs for employment had a 99% chance of having 
the financial benefit of the program outweighing the cost ($5949 versus $138) (Aos & Drake, 
2013).  However, Visher, Wintershield, and Coggeshall (2005) conducted a small meta-analysis 
of 33 ex-offender employment programs and did not find statistically improved recidivism rates.  
Alaska has already established job resources for released prisoners.  As of January 1, 2015, 
within their first 16 months of operation, PRC assisted 1,096 individuals with job training or 
employment readiness services.  Additionally, the Alaska Department of Labor and Workforce 
Development have many programs and community collaborations in place to help prisoners gain 
employment upon release (Gutierrez, 2015).  
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Housing assistance.  Having a place to live is a basic social need.  Approximately 48% 
of study participants (roughly 30% of ADOC prisoner and probation population) reported being 
homeless at least one time before incarceration.  There are many barriers to receiving housing in 
Alaska including landlord restriction on renting to those with a prior criminal record, federal and 
state restrictions on renting subsidized housing to those with a prior criminal record, and a high 
cost of rent (Gutierrez, 2015).  
Substance abuse treatment.  Drug or alcohol use is often the reason for recidivating 
(Durose et al., 2014).  Phillips (2010) conducted a qualitative study of 20 prisoners who had at 
least one prior incarceration.  Fifteen of the 20 interviewed identified substance abuse as the 
cause of recidivating.  The remaining five admitted to using substances upon release, although 
the primary reason for recidivating was not substance abuse.  ADOC estimates 80% of inmates 
have a history of abusing drugs or alcohol (Gutierrez, 2015).  The 2015 National Drug Control 
Strategy (Office of National Drug Control Policy, 2015) points out that substance misuse is a 
medical disorder that is preventable and treatable, much like any other illness.  This 2015 
Strategy was created to reduce substance abuse in the United States by creation of the following 
goals as stated by President Obama:  
Preventing drug use in our communities; 
seeking early intervention opportunities in health care; 
integrating treatment for substance use disorders into health care and supporting 
recovery; 
breaking the cycle of drug use, crime, and incarceration; 
disrupting domestic drug trafficking and production; 
strengthening international partnerships; and 
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improving information systems to better address drug use and its consequences. 
President Obama further delineated in this report that he would like to see budgeted funds of 
$133 million go towards state-level prescription drug overdose prevention, access to the opioid 
reversal agent naloxone, and Medication-Assisted Treatment (MAT) programs (Office of 
National Drug Control Policy, 2015).   
 Behavioral health treatment and counseling.  Behavioral health treatment and 
counseling is necessary for success in drug and alcohol treatment.  In fact, federal law mandates 
concurrent behavioral health interventions when treatment includes opioid replacement therapy 
for substance abuse (Substance Abuse and Mental Health Services Administration [SAMHSA], 
2015b).  Approximately six out of ten individuals who abuse drugs or alcohol also have a mental 
illness, thus necessitating concurrent treatment of counseling along with consideration for MAT 
(NIDA, 2012a).  Additionally, an estimated 65% of ADOC inmates are beneficiaries of the 
Alaska Mental Health Trust Authority (ADOC, 2014).  Approximately 30% of ADOC inmates 
have coexisting mental health and substance abuse diagnoses (Gutierrez, 2015). 
Medication-assisted treatment.  NIDA (2012a) recommends pharmacotherapy as part of 
substance abuse treatment.  They further recommend that treatment should be immediately 
available to prevent loss of the opportunity to treat.  Knudsen, Abraham, and Roman (2011) 
conducted interviews with 345 private substance abuse treatment programs and found that MAT 
was utilized in only 24% of alcohol-dependent patients and 34% of opioid-dependent patients.  
At present, there are three medications used in MAT for opioid dependency: buprenorphine, 
methadone, and naltrexone.  Naltrexone is available either orally or via an injectable extended-
release naltrexone (XR-NTX).  For alcohol-dependent individuals, the medications used for 
MAT are naltrexone, acamprosate, and disulfiram (SAMHSA, 2015b). 
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Buprenorphine.  Buprenorphine is an oral medication available in several formulations 
such as a pill or film.  It is a partial opioid agonist which can reduce withdrawal symptoms from 
opioids but can also cause euphoria and respiratory depression.  Buprenorphine requires monthly 
visits to a licensed medical doctor who is certified by the Substance Abuse and Mental Health 
Services Administration (SAMHSA) to prescribe this medication.  The Federal Drug 
Administration (FDA) states that buprenorphine is to be used indefinitely (SAMHSA, 2015b).   
Methadone.  Methadone is a synthetic opioid that helps reduce withdrawal from heroin or 
other opioids and requires monthly visits to an SAMHSA certified outpatient treatment program 
for dispensing.  It is a maintenance medication, meant to be used long-term (Office of National 
Drug Control Policy, 2012; SAMHSA, 2015b).  Methadone carries a risk of diversion and abuse, 
and there is great concern over the possibility of overdose with methadone if drug dosing is not 
carefully monitored (Oser, Knudsen, Staton-Tindall, Taxman, & Leukefeld, 2009).  
Acamprosate.  Acamprosate is used as a maintenance medication for alcohol dependency.  
It is started on day five of sobriety and is taken orally three times a day for an indefinite basis to 
reduce the desire to consume alcohol.  It does not assist with withdrawal symptoms and can be 
continued despite relapse in sobriety (SAMHSA, 2015b). 
Disulfiram.  Another medication used for chronic alcohol dependence is disulfiram, 
which is started a minimum of 12 hours after last alcohol intake.  It works by changing the 
breakdown of alcohol to form acetaldehyde.  Disulfiram will cause nausea and vomiting if taken 
while alcohol is consumed (NIDA, 2009; SAMHSA, 2015b).  
Naltrexone.  Extended-release injectable naltrexone (XR-NTX), brand name Vivitrol, 
manufactured by Alkermes, is an opioid antagonist indicated for use in recovery from opioid or 
alcohol dependency.  The FDA first approved XR-NTX for the treatment of alcohol dependence 
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in 2006 and opioid dependence in 2010 (Drugs.com, 2015).  When using XR-NTX for the 
treatment of alcohol abuse, it blocks the reward and intoxication from consuming alcohol 
(SAMHSA, 2015b).  It is not a controlled substance or addictive, has no withdrawal, and may be 
prescribed by any primary care provider for eligible patients.  XR-NTX is given via 
intramuscular injection at a dose of 380 mg every four weeks.  Those who are opioid-dependent 
need to be opioid-free for at least seven days before initiation of XR-NTX to prevent rapid 
withdrawal (Alkermes, 2013b; Office of National Drug Control Policy, 2012; SAMHSA, 
2015b).  Clinical trials for XR-NTX researched use up to six months for opioid or alcohol abuse, 
although it can be used indefinitely for those with intense cravings (Alkermes, 2013b).   
Clinical Significance 
MAT can be utilized to meet the 2015 National Drug Control Strategy goal of “breaking 
the cycle of drug use, crime, and incarceration” (Office of National Drug Control Policy, 2015).  
Although pharmacological treatment of substance abuse is recommended, only half of all Drug 
Courts in the nation utilize MAT as part of their treatment plan (National Association of Drug 
Court Professionals, 2013).  MAT is underutilized, mainly due to lack of knowledge regarding 
medication options and the benefit of their use in the treatment of addicts (National Association 
of Drug Court Professionals, 2013).  There are approximately 21 states looking at utilizing XR-
NTX in the criminal justice system (Alkermes, 2013a).   
Aletraris, Edmond, and Roman (2015) evaluated data from 307 substance abuse 
treatment programs on the prevalence of using XR-NTX as part of their treatment program.  
They found that along with cognitive behavioral therapy, only 13% used XR-NTX for alcohol 
use disorder and 3% used XR-NTX for opioid use disorder.  The availability of wraparound 
services (medical and behavioral health care, housing, and transportation services), insurance 
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coverage, and availability of inpatient detoxification contributed to the positive use of XR-NTX.  
Cost, lack of knowledge, and a lack of an inpatient rehabilitation centers were cited as negatives 
regarding the use of XR-NTX.    
 A study in Missouri conducted by Crits-Christoph, Lundy, Stringer, Gallop, and 
Gastfriend (2015) looked at 2882 released offenders with a history of alcohol or opioid abuse 
history who were in treatment for substance abuse.  They compared various agents used for 
MAT including XR-NTX, oral naltrexone, and buprenorphine/naloxone.  Of the 2882 
participants: 156 received XR-NTX, 45 received oral naltrexone, 168 received 
buprenorphine/naloxone, and 2513 received psychotherapy only.  At admission to treatment, 
45.4% were free of alcohol or drug abuse.  The percentage of improvement in abstinence at 
discharge from treatment was 66.9% for XR-NTX, 23.2% for oral naltrexone, 22.2% for 
buprenorphine/naloxone, and 17.9% for only psychotherapy.  Those treated with XR-NTX were 
more likely to achieve abstinence in comparison to all other treatment groups:  oral naltrexone (p 
= .018), buprenorphine/naloxone (p < .0001), and psychotherapy only (p = .003).  Moreover, 
they found that treatment retention time was significantly higher for XR-NTX, 95 days, versus 
oral naltrexone 59 days (p = .025) and psychotherapy only 85 days (p = .0005).  Treatment 
retention time in comparison to buprenorphine/naloxone was not significant (p = .096).  
Nationwide, MAT is underutilized (Aletraris, 2015; National Association of Drug Court 
Professionals, 2013).  ADOC utilizes MAT in their treatment plans while incarcerated and after 
release through the therapeutic courts, but they lack sufficient funding to provide for all of those 
in need (Gutierrez, 2015).  Only 10 percent of released inmates in Alaska gain access to 
supervised community-based substance abuse treatment after release—approximately 500 of 
5,000 that are candidates for treatment (Martin & Colt, 2009).  ADOC can currently treat only 
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468 individuals per year in community-based substance abuse treatment programs (Gutierrez, 
2015).  A study conducted by the Institute of Social and Economic Research at the University of 
Alaska Anchorage evaluated the economic impact of adding services within the ADOC to reduce 
criminal recidivism in Alaska (Martin & Colt, 2009).  They determined that spending $4 million 
annually from 2009 through 2030 ($124 million accounting for inflation) would save the State 
$321 million in costs otherwise dedicated to housing and construction of a new prison facility.  
Education/Vocation training and outpatient substance abuse programs save two to four times the 
expense of the program and reduce recidivism by four percent.  Residential substance abuse 
treatment, therapeutic courts, and mental health care when transitioning from prison save two to 
seven times the cost of implementation and reduce recidivism by four to 11 percent (Martin & 
Colt, 2009).  
Many view the prescribing of buprenorphine and methadone for addiction recovery as 
substituting one addictive substance for another (Oser et al., 2009; SAMHSA, 2015b).  
Nationwide, there is a trend toward using XR-NTX, instead of opioid replacement therapy, to 
treat opioid dependence.  XR-NTX is desirable because of patient preference to remain opioid-
free, its extended-release preparation that increases adherence, and the lack of withdrawal 
symptoms if a dose is missed (SAMHSA, 2012).  According to a private conversation with 
Michael Eldridge, Addiction Recovery Associate, Alkermes, on September 29, 2015, XR-NTX 
has been underutilized in the State of Alaska, in part, due to lack of access.   
 There is no single evidence-based approach for the treatment of substance abuse.  Several 
studies have evaluated and proven the efficacy of XR-NTX in reducing recidivism.  Although 
naltrexone is supported by evidence to significantly reduce alcohol and opioid misuse for 
released prisoners (Crits-Christoph et al., 2015; Coviello et al., 2012), XR-NTX is underutilized 
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in the treatment of alcohol and opioid use disorders.  There are many barriers to overcome in 
order to increase use of XR-NTX as part of a formal substance abuse treatment program.  
However, more data is needed to facilitate broad reaching adoption by states as they decide to 
utilize XR-NTX in the corrections system to reduce recidivism. 
Current Clinical Practice 
In Anchorage, recently released prisoners have difficulty accessing MAT.  Barriers to 
initiating MAT in the recently released prisoners are multifactorial.  Being uninsured or 
underinsured limits the availability and affordability of medical care needed to receive MAT 
(Gutierrez, 2015).  The recent Medicaid expansion in Alaska allows more people access 
healthcare (State of Alaska, 2015b).  However, there is limited availability of providers willing to 
see Medicaid recipients (The Foundation for Government Accountability, 2013).  Even the 
Federally Qualified Health Center in Anchorage, Alaska has a one-year backlog of patients 
waiting for appointments (Hanlon, 2015).  One of the goals of Medicaid expansion in Alaska was 
to reduce recidivism by providing access to behavioral health care and medical treatment for 
substance abuse (Gutierrez, 2015).  Healthcare providers, both medical and behavioral, need to 
take assignment of patients with Medicaid benefits to meet this goal.   
Prisoners leaving the ADOC are screened and assigned a risk score for recidivating.  The 
high-risk population released from incarceration in Alaska is referred to Partners Reentry Center 
(PRC) for consultation and wrap around services to help with successful reentry into their 
community.  High-risk individuals are those who lack resources and would likely be otherwise 
homeless upon release from incarceration, placing them at a higher probability of recidivating 
(Council of State Governments, 2015).  PRC has committed to providing substance abuse 
counseling for their clients via Moral Reconation Therapy (MRT) (Partners for Progress, n.d.).  
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There is heightened interest in getting released prisoners to choose XR-NTX to aid in the path to 
alcohol or substance abuse recovery.  PRC reported difficulty gaining access to providers willing 
to screen and administer XR-NTX and have noted a three week waiting period, which 
significantly increases the risk of chronic substance abuse in the recently released (C. 
McLaughlin, personal conversation, November 3, 2015).  Healthcare providers available for 
referrals with immediate availability are essential to the success of a recovery program utilizing 
XR-NTX.   
Question Guiding Inquiry 
Every clinical inquiry begins with a problem and a proposed solution to improve the clinical 
process.  PICOT (an acronym which stands for population, intervention, comparison, outcome, 
and timeframe) is one tool to guide inquiry of clinical practice and help define a succinct clinical 
question.  A question developed using PICOT leads to clearly defined methods, design, and data 
analysis (Melnyk & Fineout-Overholt, 2015).   
PICOT question.  Will the development of a program aimed at providing early access to 
XR-NTX upon release from incarceration reduce recidivism rates in the State of Alaska?  
 Population (P).  The population for this study was recently released prisoners (typically 
day of release) from the Alaska Department of Corrections (ADOC) with a self-reported prior 
history of opioid or alcohol abuse who have been referred to PRC in Anchorage, Alaska. 
 Intervention (I).  The planned intervention was an initiative to facilitate day of release 
access to XR-NTX as a medical treatment for those individuals who desire MAT to aid 
substance abuse recovery.  Released prisoners were educated regarding the availability, risks, 
and benefits of XR-NTX.  Practices in Anchorage willing to screen and administer XR-NTX 
were trained to provide this medical treatment.  A second intervention was collaborating with 
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PRC to facilitate access to Medicaid upon release from ADOC to improve access to healthcare.  
The pharmaceutical company Alkermes provided samples of XR-NTX for those awaiting 
medical insurance benefits through Alaska Medicaid or private insurance enrollment.  Education 
was offered to interested parole and probation officers regarding the benefits and availability of 
XR-NTX, which helped facilitate the path of released prisoners to a medical provider who could 
provide this service.   
 Comparison (C).  This project compared recidivism rates between those who voluntarily 
utilized XR-NTX and those who did not utilize XR-NTX.  This data regarding the use of XR-
NTX for recently released prisoners provided a rational foundation to create goals and expected 
long-term outcomes in regards to recidivism.   
 Outcome (O).  The purpose of this project was to reduce recidivism in Alaska by 
improving access to XR-NTX to anyone who desired this medication as a tool to aid their 
recovery from substance abuse post-incarceration.  There was not enough time to fully realize 
long-term recidivism reduction rates.  Measuring recidivism rates over a six-month time frame 
was possible.  A long-term goal, which was not likely to be achieved during the time frame of 
this project, was active ADOC involvement, preferably initiating the first injection of XR-NTX 
before release or “behind the wall” to minimize the risk of abusing a substance once a person is 
released back to their community.   
 Time (T).  The time frame for this project was 12 months from initiation to completion, 
September 15, 2015, to September 15, 2016.  Retrospective data from PRC was evaluated from 
this one-year time frame.    
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Conclusion 
According to the 2015 Recidivism Reduction Plan (Gutierrez, 2015), recidivism rates in 
Alaska are high with approximately 63% recidivating within three years of release.  Substance 
abuse is cited as the number one reason for recidivism in Alaska.  Many who are released from 
prison lack even basic resources to integrate back into their community (Gutierrez, 2015).  
Initiating a program to gain early access to MAT, specifically XR-NTX, along with behavioral 
health care, housing needs, and vocational assistance, may help reduce recidivism rates (Alaska 
Judicial Council, 2012; CASAColumbia, 2012 Gutierrez, 2015).  A successful program for 
substance abuse would be proven by adherence to a plan including MAT, as well as showing an 
ongoing reduction in rates of recidivism and a decline in the ADOC prison population.   
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Chapter II: Review of the Literature 
As prison populations continue to rise in the United States, initiatives are being 
implemented to reduce recidivism.  Medication-assisted treatment (MAT) is one part of the risk 
reduction for criminal recidivism.  Criminal justice systems are interested in exploring treatment 
options for alcohol and substance abuse that do not involve opioid replacement therapy with 
buprenorphine or methadone (SAMHSA, 2012).  Extended-release injectable naltrexone (XR-
NTX) received approval as a pharmaceutical option for alcohol dependence in 2006.  However, 
it is still a relatively new treatment for opioid addiction as it received Food and Drug 
Administration approval in 2010 (Drugs.com, 2015).   
Methodology  
 A comprehensive review of the literature was conducted to identify outcomes research 
using XR-NTX as part of substance abuse treatment in the released prisoner population.   
 Strategies.  An online search for relevant literature was carried out by searching the 
following databases: CINAHL, Cochrane Library, PsycINFO, and Pubmed using keywords: 
naltrexone and criminal justice and prison.  If no search results were found, keywords “injectable 
naltrexone” were used to avoid limiting the search results.  Only articles published from 2010 
through 2015 were included for current relevancy.  The initial search yielded 32 articles in 
CINAHL under search term “injectable naltrexone,” 13 in Cochrane Library, 13 in PsycINFO, 
and 13 in Pubmed.   
 Data evaluation.  The database searches were narrowed to include articles that pertained 
to use of XR-NTX in prisoner reentry, probation, parole, or the criminal justice system.  Most of 
the studies found in the search focusing on outcomes of XR-NTX were small sample pilot 
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studies.  No relevant articles were excluded for review due to the lack of abundance of articles 
for this population and intervention.   
Findings  
 The themes identified in existing research showed the relative newness of XR-NTX as an 
adjunct treatment for substance abuse.  The use of XR-NTX to reduce recidivism rates has been 
explored and the length of treatment studied.  Several articles reviewed the barriers to 
implementing a program that utilizes XR-NTX in the criminal justice system.  
 XR-NTX post-release to reduce recidivism.  Finigan, Perkins, Zold-Kilbourn, Parks, 
and Stringer (2011) retrospectively reviewed data from two Michigan drug courts and one 
Missouri drug court for outcomes from implementing XR-NTX injections in addition to their 
standard treatment.  They matched 32 high-risk individuals to a standard treatment group and 32 
to a group using standard treatment with the addition of XR-NTX.  The data was evaluated from 
June 2008 to December 2009, which was before the Federal Drug Administration approval in 
using XR-NTX for opioid dependency (Drugs.com, 2015).  The relative risk reduction of 69% in 
annual recidivism rates for the standard group versus XR-NTX treatment group was statistically 
significant (p < .05). 
 Lee et al. (2015b) conducted a small open-label, eight-week, proof of concept, non-
blinded, pilot study to assess the primary endpoint of abstinence from opioids in released male 
prisoners at weeks 4 and 8 following randomization to the XR-NTX treatment group (N = 16) vs 
the treatment as usual (TAU) group (N = 17).  One injection of XR-NTX was given before 
release and a second injection four weeks later.  The primary endpoint of opioid relapse at week 
four was 38% for the XR-NTX group versus 88% in the TAU group, which was statistically 
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significant (p < .004).  Other secondary endpoints were not significant, including recidivism 
rates which were 13% in the XR-NTX group versus 44% in the TAU group (p < .03).   
Coviello et al. (2012) conducted a pilot study of 61 recently released offenders with a 
history of opioid dependency.  They recruited individuals from five different sites for a voluntary 
MAT program using XR-NTX with branded Depotrex (approved by the FDA only for use in 
clinical studies).  Of the participants, 72% were incarcerated for drug-related crimes.  A baseline 
urine drug screen and a six-month follow-up urine drug screen were obtained, along with a self-
reporting questionnaire.  Forty percent of participants received six injections of XR-NTX, and 
64% received three injections.  Of the 74% of participants that completed the six-month follow-
up, they found 15% of study completers had been re-incarcerated in comparison with 50% of 
non-completers, which was statistically significant (p = .011).  Half of the total participants were 
employed at the six-month follow-up.  Although not statistically significant (p = .311), 
completers of the study were more likely to be employed than non-completers (56 versus 39%).   
Length of treatment.  An open-label randomized controlled trial by Gordon et al. (2015) 
explored the relationship between the length of treatment with XR-NTX and criminal recidivism.  
Of the 27 study participants recruited while incarcerated, 10% completed seven monthly 
injections of XR-NTX, with the first injection administered before releasing from incarceration.  
Although not statistically significant (p = .123), none of the 10% who completed six community 
injections of XR-NTX recidivated compared to 31.3% who completed less than six.  A nine-
month follow showed that none who completed seven injections total were opioid positive versus 
non-completers (p = .003).  
Lee et al. (2015a) conducted an 18-month, five sites, open-label randomized, controlled 
clinical trial that recruited 308 community-based individuals with prior criminal justice system 
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involvement to evaluate the primary endpoint which assessed the rate of being opioid-free at 27 
weeks after six monthly XR-NTX injections.  Of the 308, 153 were randomized to the XR-NTX 
group and 155 to the treatment as usual (TAU) group.  The XR-NTX group retention was 74% 
for six months with an opioid relapse rate of 43% in the XR-NTX group versus 56% in the TAU 
group.  Results from this study were reported as preliminary findings, with final results pending.  
Lapham and McMillan (2011) conducted a small pilot study looking at the administration 
of XR-NTX for three months for offenders involved in the criminal justice system due to charges 
of driving under the influence.  Eleven volunteers participated in this study, of which 10 received 
at least one injection of XR-NTX and seven received all three injections.  Among all 11 
participants, abstinence in alcohol increased by 31% from 56.8 to 82.0 alcohol-free days.  The 
number of daily alcoholic drinks decreased by 77% from 3.0 to 0.7 which was statistically 
significant (p < .01).  The authors recognized that a large randomized controlled trial is needed to 
assess the validity of these findings. 
Limitations 
  There are few published studies regarding the use of XR-NTX in the criminal justice 
system or with the prisoner reentry population.  The studies available utilized very small sample 
sizes and most were pilot studies.  Although the mechanism of action for XR-NTX is different 
for alcohol addiction compared to an opioid addiction, studies for either population showed 
statistically significant efficacy of XR-NTX in significantly reducing recidivism and substance 
misuse.  To gain validity and prove reproducibility, more published data is needed on the use of 
XR-NTX in the prisoner population.   
New studies for XR-NTX and prisoner reentry.  The ClinicalTrials.gov database was 
also searched in attempts to discover future studies using keywords naltrexone and prison.  
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Several trials in this database were found that aimed to evaluate the efficacy of XR-NTX and 
recidivism.  The University of California, Los Angeles (2014) planned a study comparing 
individuals randomized to the use of XR-NTX, or XR-NTX with additional services of a patient 
navigator, or a drug education program without MAT, in order to assess the efficacy of 
treatments initiated prior to release from prison on community success and opioid relapse six 
months post release.  The University of Oslo (2012) recruited inmates for a study that compared 
the success of XR-NTX versus buprenorphine-naloxone in post-release success at staying 
opioid-free at 12 weeks post release.  The results are not available, but the study is closed.  The 
University of Pennsylvania (2015) conducted research on 200 inmates randomized to pre and 
post release doses of XR-NTX to assess six-month outcomes pertaining to opioid relapse and 
recidivism rates with a goal of promoting initiating of XR-NTX before releasing from 
incarceration.  Results are not yet available.   
Rhode Island Hospital (2012) has completed a study assessing the use of XR-NTX pre 
and post release from incarceration and followed opioid relapse and recidivism rates at six, 12 
and 18 months.  Participants received six injections of XR-NTX and were randomized to receive 
their first injection before release from incarceration or to have all six injections in the 
community.  Results of this study are unpublished.   
New York University School of Medicine (2010) has completed a study comparing 30-
day post-release opioid relapse rates of inmates who received XR-NTX before release from 
incarceration and a controlled group who received standard counseling.  Results of this study are 
pending.  New York University School of Medicine (2013) is recruiting for participants among 
jail inmates, and plans to randomize participants to post-release doses of XR-NTX and treatment 
as usual to assess time to opioid relapse over 24 weeks with secondary endpoints examining 
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recidivism rates, cost-effectiveness of treatments, and a planned comparison with a non-
randomized jail-initiated methadone treatment group. 
A NewsBank literature review to look for other new developments in the use of XR-NTX 
in the prisoner population was conducted for years 2015 and 2016 using keywords naltrexone 
and prison.  This search yielded 230 articles in the United States of America.  The recent influx 
of news primarily speaks to the growing interest in using XR-NTX in the criminal justice realm 
as a means to reduce recidivism and improve health outcomes regarding substance abuse.  
Although not all of the articles reference published or ongoing research pertaining to XR-NTX, 
they do show there is an emerging nationwide effort towards achieving sobriety and reducing 
recidivism through the implementation of XR-NTX in addition to existing treatment programs. 
Conclusion 
 Recent research studies show there is a benefit to utilizing XR-NTX as part of a program 
for prisoner reentry aimed at reducing recidivism.  However, there is limited published evidence 
on this topic, and most studies published evaluated small populations.  XR-NTX offers a non-
opioid replacement option for treatment of substance abuse.  With the average cost of XR-NTX 
between $800 and $1200 per month, it is not surprising that cost is a barrier to providing this 
treatment for those with opioid or alcohol abuse histories (Alanis-Hirsch et al., 2015).  A cost-
analysis study showed the increased efficacy of XR-NTX over opioid agonist options, even 
though the cost for XR-NTX was significantly higher.  The high upfront cost is likely a limiting 
factor for most criminal justice systems when treatment options are considered (Jackson, 
Mandell, Johnson, Chatterjee, & Vanness, 2015).  Expansion of Medicaid in many states makes 
it easier to fiscally implement and sustain a treatment program that utilizes XR-NTX for alcohol 
and substance abuse treatment (Centers for Medicare & Medicaid Services, 2014).  With Alaska 
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correctional facilities at 101% capacity (Gutierrez, 2015), it is prudent to explore options that 
reduce recidivism which include additional studies to analyze the long-term cost effectiveness of 
XR-NTX in the criminal justice setting.   
 The limitations in available research show that XR-NTX is an emerging treatment option 
that appears promising in early studies.  There is a call to utilize evidence in efforts to reduce 
recidivism.  Alcohol and opioid abuse treatment options using XR-NTX need to be further 
explored in the setting of prisoner reentry to see if this will significantly reduce recidivism rates 
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Chapter III:  Organizational Framework 
Healthcare providers have significant work to do in providing evidence-based care for 
substance abuse.  A report from a five-year meta-analysis published by the National Center on 
Addiction and Substance Abuse at Columbia University (2012) showed that despite substance 
abuse being a diagnosable disease state, only one out of 10 substance-addicted individuals 
(excluding nicotine) receive any treatment, let alone treatment that is evidence-based.   
Alaska Department of Corrections screens all of its inmates for substance abuse using the 
Simple Screening Instrument-Revised (SSI-R) assessment tool, however, they do not have the 
capacity to provide residential substance abuse treatment for the high volume of inmates for 
whom residential treatment is indicated.  According to Gutierrez (2015), the fiscal year 2013 
showed the capacity for residential treatment was 228 individuals when 793 individuals were 
identified as needing residential treatment according to the SSI-R.  The outpatient substance 
abuse treatment capacity was adequate in 2013.  Suggestions made by the Alaska 2015 
Recidivism Reduction Plan recommend looking at policy changes that will provide residential 
treatment in conjunction with examining other measures to reduce recidivism (Gutierrez, 2015).  
 The Council of State Governments published the “Report of the Re-entry Policy Council” 
as the benchmark document for implementing initiatives and policy changes to benefit offender 
reentry (n.d.).  Within this document, policy statement 32 addresses substance abuse treatment 
and policy statement 35 addresses improving health outcomes and reducing costs through 
improving access to quality care in the community upon release.  Initiatives to move providers 
towards evidence-based practice are necessary for optimal outcomes in regards to substance 
abuse treatment, reduction in recidivism, and improved health. 
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Evidence-Based Practice Model   
  A quality improvement (QI) initiative uses evidence to make changes in the healthcare 
system to improve patient care outcomes.  There are many QI models that can be used as a 
systematic approach to guide change (Moran, Burson, & Conrad, 2014).  The Council of State 
Governments recommends using a logic model to make it easy for stakeholders and policy 
makers to identify the participants and goals of an initiative involving prisoner reentry (n.d.).  A 
logic model (Appendix A) is a simple visual model that can be used to plan, design, implement, 
and continually evaluate the implementation of a program and is often used to help program 
administrators and policymakers understand the full scope of the project.  The model clearly 
identifies the process of implementation by showing inputs and activities that move towards 
arriving at the desired outputs, outcomes, and the impact made by implementation of the 
initiative.  Various stakeholders contribute to different parts of the program, although there is a 
connection between all as detailed in the logic model.  Logic models may utilize a theoretical 
approach to more clearly evaluate a process.  This type of approach is often used when applying 
for funding as it incorporates the overall goal when looking at the implementation of one specific 
program (W.K. Kellogg Foundation, 2004).  Inherent to using a logic model is to address 
assumptions that preempt the planned program implementation (Council of State Governments, 
n.d.).  Appendix B shows the logic model and assumptions for the planned initiative to reduce 
recidivism by facilitating early access to extended-released injectable naltrexone (XR-NTX).  
Vision and mission.  Facilitate early access to XR-NTX for released prisoners, while 
educating healthcare providers about the use of XR-NTX to aid substance abuse treatment.  
Goal.  Reduce recidivism rate.  
Assumptions.  There are several assumptions for this project.   
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• Recidivism affects our community and partnerships formed within our 
community will help improve recidivism.   
• Expanding Medicaid in the State of Alaska will improve access to care and 
substance abuse treatment.   
• Shifting revenues to provide for early access to XR-NTX will improve health 
outcomes and reduce recidivism.   
• Our community can unite to shape policy at local and state levels as it pertains to 
recidivism. 
Inputs.  Funding, Partners Reentry Center, clients, Alkermes and primary care providers 
all contribute to the effort of the initiative. 
Activities.  Create relationships with primary care providers who can see clients in a 
timely fashion, and are willing to screen and provide XR-NTX.  Educate those involved with 
prisoners about XR-NTX.  Secure sample medication and medication information from 
Alkermes. 
Outputs.  The number of sites administering XR-NTX and the number of offenders who 
chose to receive XR-NTX. 
Outcomes.  The percentage of offenders who accepted XR-NTX, the percentage of 
offenders who did not accept XR-NTX, the percentage of offenders who recidivated and 
accepted XR-NTX, and the percentage of offenders who recidivated and did not accept XR-
NTX.  
Impact.  The effectiveness of the QI facilitating early access to XR-NTX and the 
reduction in recidivism can be measured using the retrospective data obtained from PRC.  
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Theoretical Framework 
Michie, van Stralen, and West (2011) created the Behaviour Change Wheel based on an 
analysis of 19 different behavioral health frameworks (Appendix C).  They developed their 
model to look at the factors influencing behavior change and interventions that need to occur as 
the basis for creating changes in evidence-based practice and public health policy.  The center of 
the model is the “COM-B” model, showing that capability and opportunity drive motivation and 
that all three are necessary to drive behavior change.  There are nine interventions around the 
central behavior model, which can be used to drive change: education, persuasion, 
incentivisation, coercion, training, restriction, environmental restructuring, modeling, and 
enablement.  Several interventions in the Behaviour Change Wheel could be further defined to 
improve accessibility and use of XR-NTX in the recently released prisoner population.  
Education.  Education needs to occur to teach inmates about drug and alcohol abuse 
treatment and availability of XR-NTX.  Primary care providers in the community need education 
on the use of MAT and XR-NTX for adjunct treatment for substance abuse. 
Persuasion.  Communicating benefits of XR-NTX and how the released prisoner's lives 
will change for the better could be viewed as positive persuasion.  
Incentivisation.  When used in the therapeutic court system, incentives could be 
considered by offering a lesser probation/parole period.  For those who would be otherwise 
homeless, providing safe housing is motivation to stay clean and sober. 
Training.  Training primary care providers, substance abuse treatment centers, the 
department of corrections and the re-entry facilitators about the benefits and availability of XR-
NTX will facilitate use. 
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Environmental restructuring.  Environmental restructuring could remove physical or 
social barriers to enable immediate access to the healthcare system for those who require timely 
injection with XR-NTX before recurrent substance abuse occurs.  
Modelling.  Modeling would be used to look at existing data from corrections programs 
who have implemented the use of XR-NTX post release.  
Enablement.  Enablement could be used to obtain grant funding based on data obtained 
from implemented service programs aimed at reducing recidivism. 
Conclusion 
A logic model was succinctly designed and was used to drive this QI initiative facilitating 
early access to XR-NTX for recently released prisoners.  The model allows for ongoing 
evaluation and can be further used to evaluate if this initiative is cost beneficial to a larger 
system, like the Alaska Department of Corrections.  The Behaviour Change Wheel model can be 
used to identify barriers to the use of XR-NTX to aid recovery from substance abuse.  
Overcoming these barriers will help guide policy changes that are necessary to make XR-NTX 
more accessible to those recently released from incarceration who suffer from substance abuse. 
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Chapter IV:  Project Design 
This project aimed to create early access to XR-NTX for recently released prisoners in 
Anchorage, Alaska and subsequently evaluated its effectiveness in reducing recidivism.  Partners 
Reentry Center (PRC), a non-profit organization, agreed to collaborate for the purpose of this 
project (Appendix D).  The aim was to create a succinct referral process for those who desire 
extended-release injectable naltrexone (XR-NTX) to aid in recovery from substance abuse with 
the goal to ultimately reduce recidivism in the State of Alaska.  This initiative identified several 
barriers to overcome, mainly the lack of healthcare providers knowledgeable, willing, and able to 
provide timely access to XR-NTX.  PRC collects data for each client they assist.  Anonymous 
retrospective data was accessed one-year post implementation of this project to evaluate the 
impact of XR-NTX on recidivism in Alaska.   
There are various types of projects that evaluate, implement and generate knowledge for 
clinical practice including evidence-based practice, evidence-based quality improvement, and 
clinical research (Melnyk & Fineout-Overholt, 2015).  Clinical inquiry involving human subjects 
needs to be reviewed by an Institutional Review Board (IRB) to ensure the protection of human 
subjects.  An IRB application was made to the University of Alaska Anchorage IRB before 
implementation of this project.  
Institutional Review Board 
The IRB at the University of Alaska Anchorage reviews project proposals to ensure the 
safety and well-being of research participants and a fair selection of study participants according 
to federal guidelines (University of Alaska Anchorage, 2012).  There are three levels of IRB 
review including exempt, expedited, and full review.  The U.S Department of Health and Human 
Services (HHS) discusses prisoner research in depth in 45 CFR part 46, subpart C (2009).  The 
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extent of human subject involvement, type of project, and scope of outcomes reported 
determines the level of IRB review.  Ethics and confidentiality are important conditions to 
consider when doing research regarding a vulnerable population (Gordon, Kinlock, & Miller, 
2011).  An IRB Determination Form was submitted for approval of this project.  The UAA 
Compliance Officer determined this project did not involve human subjects and was exempted 
from IRB review (Appendix E). 
Evidence-based practice.  A project that focuses on evidence-based practice uses 
existing evidence and incorporates it into practice (Melnyk & Fineout-Overholt, 2015).  
Although there is a body of research regarding XR-NTX, it is not yet highly utilized as a 
mainstream treatment for alcohol or opioid addiction, particularly within the State of Alaska.  
This project educated attendees at the September 2016 Alaska Nurse Practitioners Association 
conference about medication-assisted treatment (MAT) and XR-NTX, including its use in the 
prisoner population, with the goal of increasing access to substance abuse treatment within 
primary care.  
Evidence-based quality improvement.  While this project utilized evidence-based 
practice, the focus was on implementation strategies to improve access of XR-NTX to recently 
released ADOC population, and to evaluate the effectiveness of this strategy to reduce 
recidivism.  Implementation strategies to improve clinical practice in regards to the use of XR-
NTX in the medical treatment of alcohol or opioid addiction as an evidence-based treatment 
option were also developed.  Given the small body of published knowledge on the use of XR-
NTX in the prisoner population, this project will add to the evidence for the use of XR-NTX. 
Clinical inquiry.  Clinical inquiry and evidence-based quality improvement methods 
should give consideration to seven ethical principles including scientific and social value, 
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scientific validity, fair subject selection, favorable benefit compared to risk, independent review, 
respect for potential and enrolled subjects, and informed consent (Melnyk & Fineout-Overholt, 
2015).   
 Scientific and social value.  Using XR-NTX to reduce recidivism and potentially reduce 
substance-related crime has clear social value.  Sharing statistical outcomes relating the use of 
XR-NTX and recidivism rates will add to the body of science.  
 Scientific validity.  Utilizing evidence-based medicine to implement a Quality Initiative 
will minimize risk to participants and should result in a rigorous project. 
 Fair subject selection.  Participants in the project all volunteered to use XR-NTX thus 
avoiding the potential for coercion which is a basic tenant of human research subject protection.
 Favorable risk-benefit ratio.  Risks associated with XR-NTX include, but are not 
limited to any injection site reaction, hepatotoxicity, depression or suicidal ideation, allergic 
reaction, eosinophilic pneumonia, a risk of an opioid overdose after cessation of XR-NTX, or 
risk of opioid withdrawal with the initiation of XR-NTX (Alkermes, 2013c, 2015).  Despite the 
risks listed in the product information, the discontinuation rate of XR-NTX versus placebo was 
9% versus 7% for alcohol-dependent patients and 2% for both XR-NTX versus placebo in 
opioid-dependent patients (Alkermes, 2015).  Clinical trial outcomes data using XR-NTX for 
alcohol-dependent patients showed significantly fewer heavy drinking days (defined as more 
than five daily drinks for males and four daily drinks for females) compared to placebo 
(Alkermes, 2015).  Krupitsky et al. (2011) conducted a 24 week, randomized controlled trial on 
the efficacy of XR-NTX for opioid dependency on 250 participants. The group assigned to XR-
NTX (N = 126) had statistically significant higher median number of weeks of abstinence 
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compared to the placebo group (N = 124), 90% versus 35% respectively (95% CI, p = .0002).  It 
would appear that the potential for benefits of receiving XR-NTX outweighs the risks.  
XR-NTX is supported by evidence to significantly reduce alcohol and opioid misuse for 
released prisoners (Coviello et al., 2012; Crits-Christoph et al., 2015).  The benefits of 
facilitating access to XR-NTX in a timely fashion may help reduce the risk of recidivism due to 
substance abuse while on probation.  Subjects who seek a referral to a community medical 
provider for the purpose of receiving XR-NTX benefited from a medical screening, which may 
identify other health needs.  Sample medication of XR-NTX may be utilized to begin treatment 
for those with no medical benefits.  
 Independent review.  IRB review ensured ethical use of data regarding participants in 
this project. 
 Respect for potential and enrolled subjects.  This project leader had no direct contact 
with participants and no ability to influence participation.  XR-NTX treatment is a personal 
choice and is offered as an option for adjunctive treatment by PRC.   
Informed consent.  The U.S. Department of Health and Human Services OHRP 
publishes decision charts about human subject research to determine the level of IRB review and 
the requirement for participant consent (2004).  Chart 10 explores the obligation to provide 
informed consent for participation in human subject research.  XR-NTX was offered by PRC 
staff to appropriate clients presenting to PRC as an adjunct treatment in alcohol or opioid abuse 
recovery.  The use of XR-NTX is not experimental and has documented evidence of statistically 
significant efficacy in the department of corrections population as noted in the review of the 
literature.  Participant consent was not required as only de-identified data was ascertained from 
PRC from statistical data already collected on participants at PRC.  Also, released prisoners 
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choose whether or not to utilize extended-release injectable naltrexone (XR-NTX) as part of their 
substance abuse treatment.  A letter of support from Partners for Progress (Appendix D) was 
provided outlining their collaboration and willingness to provide de-identified data for the 
purpose of measuring the outcomes of this evidence-based practice initiative.   
Evidence-Based Practice Change Design 
 The logic model framing this project (Appendix B) offers a clear visualization of the 
initiative and the expected short and long term outcomes that were reported.  The primary 
stakeholders in this initiative can easily identify where their participation is imperative.  The 
expected outcomes and community impact of this evidence-based implementation project are 
also easily visualized. 
Leadership.  A quality improvement initiative will only be successful with the right 
people influencing and moving towards change.  Initiating early access to XR-NTX required 
healthcare providers willing to screen and utilize medically assisted treatment to aid in the 
treatment of alcohol or opioid abuse.  With the assistance of PRC and other existing and new 
community partners, this project intended to reduce barriers and create solutions to implementing 
early access to XR-NTX with a long-term goal to reduce recidivism.  This initiative also sought 
to drive funding and policy change to further efforts towards access to XR-NTX. 
Quality improvement team.  PRC, probation and parole officers, judicial employees, 
and community healthcare providers were all involved in this quality improvement initiative.  
Partners for Progress holds bimonthly meetings with the principle stakeholders with the goal to 
reduce recidivism and improve prisoner success at community reentry in the State of Alaska.  
These meetings provided a forum to discuss all matters about recidivism and prisoner reentry.  
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Materials and equipment.  Patient education on XR-NTX was made available to PRC, 
healthcare providers, and anyone else in direct contact with participants interested in receiving 
XR-NTX (Appendix F).  
Methodology and resources.  An initial meeting at Partners Reentry Center on 
September 15, 2015, with the Director of Partners Reentry Center and the Chair of the Board for 
Partners for Progress identified the desire to implement an initiative to gain access to XR-NTX 
as part of substance abuse treatment for high-risk recently released prisoners.  Limited grant 
funds were available to provide screening and administration of XR-NTX if sample medication 
was available.  Anonymous data was provided by PRC to evaluate the success of the initiative 
using XR-NTX to reduce recidivism. 
Barriers to overcome.  PRC identified several existing barriers to implementing this 
initiative.  Currently, there is a lack of community providers willing or knowledgeable enough to 
administer XR-NTX.  Another barrier identified was the amount of time until an appointment to 
administer XR-NTX, which increased the risk for substance abuse in time frame between release 
and injection with XR-NTX.  The cost of XR-NTX and lack of insurance coverage were also 
identified as a significant barrier to providing adjunct treatment with XR-NTX.  For this 
initiative to move forward, plans to overcome identified barriers to implementation were 
addressed.  
Community providers.  Provider willingness to be a referral source for the administration 
of XR-NTX is a critical piece of this initiative.  Alkermes utilizes an Anchorage-based Addiction 
Recovery Specialist to educate healthcare providers across the state (including behavioral health, 
substance abuse programs, and primary care providers).  Education is the fundamental 
component of facilitating awareness and efficacy regarding XR-NTX.   
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Time to administration.  Providers and their support staff willing to be a referral source 
for the administration of XR-NTX were educated on the need for timely administration of XR-
NTX post-release. 
Cost and coverage of XR-NTX.  If participants did not have medical benefits, they were 
assisted by personnel at PRC in applying for Alaska State Medicaid which would help fund 
ongoing treatment.  Alkermes was generous in providing XR-NTX samples to providers willing 
to facilitate early access post prisoner release for uninsured or underinsured individuals who 
desired treatment with XR-NTX.  Alkermes has historically funded “first shot behind the wall” 
programs if the department of corrections is willing to adopt this policy for interested prisoners 
(Beck, 2015), and they have expressed willingness to provide samples to the ADOC.  
Challenges of Collaboration 
High-risk prisoners reentering their community require reliable resources to facilitate 
their success.  Anticipated barriers in this initiative to facilitate early access to XR-NTX for 
recently released prisoners were considered.  These included waning interest in the initiative as 
time progresses, lack of provider willingness to become educated regarding XR-NTX, increased 
demand on the few facilities who are willing to provide XR-NTX causing delay in initiating XR-
NTX, funding availability for XR-NTX screening and administration, lack of timely access to 
Alaska State Medicaid or other insurance coverage post-release, reduced availability of XR-NTX 
sample medication that will facilitate early access regardless of insurance benefits, and perceived 
high risk/ low benefit by released prisoner in regards to use of XR-NTX.   
Plan for Project Evaluation 
Process improvement and policy needs to be directed at appropriate treatment of 
addiction to drugs or alcohol as a means to reduce recidivism.  Many released from prison lack 
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access to recovery resources for substance abuse.  Initiating a program to facilitate early access 
to counseling and XR-NTX for those recently released from incarceration may help reduce 
recidivism rates.  The outcomes measured to evaluate the effect of XR-NTX on recidivism could 
support policy change if outcomes were significant. 
Data collection and analysis.  PRC serves clients that voluntarily present for community 
reentry assistance upon release from incarceration.  These clients either self-refer or are referred 
by the Alaska Department of Corrections based on Level of Service Inventory-Revised screening 
conducted before release.  Data is collected on all clients served through PRC.  Demographic 
data is collected including gender, race, and age.  PRC also receives extensive information about 
the criminal history and social history including substance abuse history.  Clients with a history 
of alcohol or opioid abuse are educated regarding and offered access to XR-NTX as part of a 
comprehensive treatment program along with Moral Reconation Therapy (MRT).  Client 
participation in treatment with XR-NTX is not tied to probation or utilized as a bargaining tool 
for receipt of other services.  PRC tracks data on their clients in regards to alcohol or opioid 
abuse history, whether or not the client was offered and received XR-NTX as part of a treatment 
program, and recidivism.  PRC prepares quarterly reports that offer de-identified data.  Outcomes 
data reported for this project include numbers served, use and declination of XR-NTX, 
recidivism rates for those who opted to use XR-NTX, and recidivism rates for those who did not 
utilize XR-NTX.  
Post intervention plans.  After obtaining outcomes data, the information was presented 
to the ADOC for consideration regarding the utilization of XR-NTX as an adjunct to reduce 
recidivism and treat substance abuse.  This project may motivate government officials to initiate 
changes in policy with regards to parole to include an emphasis on the use of XR-NTX instead of 
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opioid replacement therapies, with consideration for the first injection of XR-NTX given before 
release from the DOC to minimize risk for substance misuse and subsequent recidivism after 
release from incarceration.  The outcomes of this project should convince ADOC that adequate 
resources exist to continue the adjunctive treatment of prisoners upon release to communities 
across the state.  The findings generated by this project will hopefully be beneficial to ascertain 
future funding for PRC.  
Conclusion 
XR-NTX is an effective tool in reducing rates of recidivism in those with a prior history 
of alcohol or opioid use.  A small number of studies throughout the United States have shown 
promising data when utilized in prisoner populations.  One barrier to using XR-NTX in the 
Anchorage community was a lack of primary care providers who have received education on 
substance abuse and use of XR-NTX, as well as having sites available for immediate screening 
and administration of XR-NTX.  A delay in screening and care may result in recurrence in 
substance misuse and subsequent recidivism, so timing is critical to the success of this program.  
This project found healthcare providers willing to provide XR-NTX and receive knowledge of 
MAT and the use of XR-NTX.  Another barrier to utilization of XR-NTX is cost.  Expansion of 
Alaska Medicaid eligibility increased access to substance abuse treatment; many qualify for 
Medicaid benefits upon release from incarceration.  Enrolling individuals in Alaska Medicaid 
would alleviate a financial barrier to obtaining XR-NTX.  Samples have historically been 
provided by Alkermes to facilitate early access to XR-NTX, but, for program sustainability, 
insurance coverage is required.  PRC greatly assisted in the implementation of this XR-NTX 
access initiative.  This project provided early data on recidivism rates for released prisoners who 
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choose to use XR-NTX as an adjunct to other services provided by PRC.  The State of Alaska 
should appreciate the continued decline in recidivism rates for those former inmates who 
participate in substance abuse treatment.   
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Chapter V:  Implementation Process and Procedures 
This project utilized a logic model to guide implementation of providing access to 
extended-release injectable naltrexone (XR-NTX) for recently released prisoners (Appendix B).  
Having a clear set of activities needed for project implementation increases the chance of 
successful outcomes (W.K. Kellogg Foundation, 2004).  The activities listed in the logic model 
for this project generated data that was critical for gauging its success.  Also, the Behaviour 
Change Wheel (Appendix C) (Michie, van Stralen, & West, 2011) was utilized to guide 
interventions that needed to occur to support integrating evidence-based practice and public 
health policy.   
Project Implementation 
The logic model provided a visual model to help all stakeholders involved in the 
implementation of this project.  The model provided four clear steps or activities that needed to 
be accomplished to show the success of this project.  The expected outcomes and impact to the 
community were also anticipated. 
Establishing relationships.  The first step or activity was building relationships with 
local providers involved in substance abuse treatment.  Through networking with the assistance 
of Michael Eldridge, Addiction Recovery Associate from Alkermes pharmaceutical company, 
primary care providers were identified in the community who would be interested in 
administering XR-NTX.  Local substance abuse treatment programs were also approached 
regarding the potential benefits of XR-NTX during recovery.  This step was largely implemented 
through phone consultations and in-person discussions with interested providers and healthcare 
organizations which included lengthy deliberations on the importance of early access to XR-
NTX upon release from incarceration and the importance of timely follow-up injections.  
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Implementation of medication-assisted treatment (MAT) in the clinic setting.   
Although XR-NTX has had FDA approval since 2006 for alcohol dependency and 2010 for 
opioid dependence (Drugs.com, 2015), medication-assisted treatment (MAT) is still vastly 
underutilized likely due to a lack of knowledge regarding medication use and benefits (National 
Association of Drug Court Professionals, 2013).  Primary care providers are in a prime role for 
screening and initiation of treatment for those with a history of substance abuse.  For this project, 
many providers needed comprehensive education regarding the use of XR-NTX.   
Screening for substance abuse history.  The Substance Abuse and Mental Health 
Services Administration (SAMHSA) developed the Screening, Brief Intervention, and Referral 
to Treatment (SBIRT) program as an evidence-based model for detecting substance abuse risk 
(2016b).  The first step in SBIRT is to identify those at risk of substance misuse.  It is 
recommended that healthcare providers initially ask all patients “How many times in the past 
year have you used an illegal drug or used a prescription medication for non-medical reasons?” 
(Smith, Schmidt, Allensworth-Davies, & Saitz, 2009).  The National Institute on Drug Abuse 
(NIDA) modified this question and created the NIDA Quick Screen Question (Appendix G) to 
screen for alcohol and tobacco use successfully (2012b).  Any positive response to the NIDA 
Quick Screen question should prompt additional screening.  If the patient answers yes to more 
than one day of heavy drinking, NIDA recommends that the healthcare provider reviews the 
publication “How to Help Patients Who Drink Too Much: A Clinical Approach” (NIDA, 2005).  
NIDA recommends using the NIDA-Modified ASSIST if the patient states they used illegal or 
prescription drugs for nonmedical reasons (Appendix G) (2012b).  An available online version of 
the NIDA-Modified ASSIST tool with automatic scoring, risk assessment, and appropriate 
recommendations for follow-up is available at https://www.drugabuse.gov/nmassist.  It is also 
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possible to link this screening tool directly to a healthcare provider electronic health record 
(NIDA, 2012b).  Healthcare providers can code for reimbursement for conducting SBIRT 
screening if an intervention is required; otherwise, the office visit charge includes the screening:   
Table 5.1  
Reimbursement for SBIRT 
 
Substance Abuse and Mental Health Services Administration. (2015a). Coding for screening and 
brief intervention reimbursement. Retrieved from  http://www.samhsa.gov/sbirt/coding-
reimbursement 
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Screening for depression.  Given the listed side effect of depression (5%) and suicidal 
behavior (5%) associated with XR-NTX use (Alkermes, 2013b; American Association for the 
Treatment of Opioid Dependence [AATOD], 2016), it is recommended to have the patient 
complete a depression screening tool such as the Patient Health Questionnaire-9 (PHQ-9) 
(Appendix H) (Kroenke & Spitzer, 2002).  If there are any concerns regarding the presence of 
depression or other mental health disorders, a mental health evaluation should be conducted, and 
underlying depression or mental health disorders should be treated concurrently with substance 
abuse treatment.  
Screening for the appropriate XR-NTX candidate.  SAMHSA has developed a pocket 
guide for MAT of opioid use disorder that has a checklist to aid in the selection of the 
appropriate patient (Appendix I) (2016a).  They recommend assessing the need for MAT by 
determining the risk level of the patient’s substance use disorder, which can be quantified by the 
NIDA-Modified ASSIST.  Also, the healthcare provider should complete a patient history and 
exam and identify co-morbid health conditions.  Providers also need to review their state’s 
Prescription Drug Monitoring Program website to gain more clinical insight on the patient 
regarding prior prescription medication use.  Recommended laboratory testing includes urine 
drug screen for current opioid and other drug use, urine test for alcohol, liver enzymes, serum 
bilirubin, serum creatinine, hepatitis screening, and HIV testing.  Providers should also assess for 
each patient’s need for medically managed withdrawal from opioids or alcohol (SAMHSA, 
2016a).  The Alkermes website for XR-NTX has a patient counseling checklist (Appendix F), 
which can be used to educate the patient about the use of XR-NTX and also helps the healthcare 
provider screen for the patient for appropriate treatment with XR-NTX (Alkermes, 2016).  
Patients who are candidates for MAT with XR-NTX must be free from opioid use for at least 
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seven to 10 days and possibly up to 21 days for longer acting prescription opioids such as 
buprenorphine and methadone, to prevent precipitation of opioid withdrawal.  Patients should not 
be actively drinking alcohol when they receive their XR-NTX injection (Alkermes, 2016).  
Administration of XR-NTX.  If the patient reports recent opioid use or there is a concern 
of precipitating withdrawal, you can consider offering a test dose of oral naltrexone using 
12.5mg-25mg (AATOD, 2016).  The Clinical Opiate Withdrawal Scale (COWS) (Appendix J) 
can be used to clinically assess for symptoms of opioid withdrawal before administration of XR-
NTX and can be used to monitor for potential progression of withdrawal symptoms when 
utilizing a trial dose of oral naltrexone (Wesson & Ling, 2003).  The Clinical Institute 
Withdrawal Assessment of Alcohol Scale-Revised (CIWA-ar) (Appendix K) can be used to 
assess the severity of alcohol withdrawal and the need for MAT.   
After the screening, if the patient is found to be a candidate for XR-NTX, 380 mg of XR-
NTX is given every 28 days via a deep intramuscular injection.  It is mixed using the package 
contents which include the medication and diluent and is administered using the enclosed 1½-
inch or 2-inch needle, depending on the amount of subcutaneous fat that is present.  It is 
important to inject the medication into the muscle tissue to prevent an injection site reaction, 
which could be severe (Alkermes, 2015).  
Through the duration and efforts of this project, XR-NTX is now predictably stocked in 
most Anchorage pharmacies.  The billing for screening and administration of XR-NTX includes 
an evaluation and management office visit code and the XR-NTX administration fee in addition 
to a fee for SBIRT screening if appropriate.  At one clinical setting, the healthcare providers 
found it beneficial to have a face-to-face visit with the client at their follow-up dosing to ensure 
accountability, support, and to assess client participation in a substance abuse treatment program. 
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Community outreach.  Community outreach was the second activity listed within the 
logic model.  Education, persuasion, and training were three of the nine recommended 
interventions utilized during this activity from the Behaviour Change Wheel (Appendix C) 
(Michie, van Stralen, & West, 2011).  Outreach to community stakeholders needed all three of 
these interventions simultaneously to promote the use of XR-NTX.  Outreach on the potential 
use of XR-NTX as a tool for substance abuse treatment occurred at Anchorage Therapeutic 
Courts, Partners Reentry Center, and local inpatient rehabilitation centers.  Briefings and 
education on the XR-NTX access project occurred bi-monthly during Partners for Progress board 
meetings in Anchorage.  A discussion included the referral process for immediate screening and 
administration of XR-NTX for appropriate candidates.  Participation in panel discussions on 
prisoner reentry, including the use of XR-NTX by the project leader occurred at the March 2016 
“Reducing Recidivism through Successful Reentry” conference and the May 2016 “Annual 
School on Addictions” conference in Anchorage, Alaska.   
Incentivisation and environmental restructuring.  The Behaviour Change Wheel 
interventions of both incentivisation and environmental restructuring were used to promote 
utilization of XR-NTX as a potential means to reduce recidivism along with structured support 
services and comprehensive substance abuse treatment programs.  A total of 98 individuals were 
offered XR-NTX through the Partners Reentry Center during the implementation phase from 
September 15, 2015, through March 15, 2016.  Of these, 60 accepted treatment with XR-NTX 
and 38 declined.  Housing was provided for 82 of the total project population.  Those accepting 
XR-NTX were often housed at the same facility.  
Funding.  The third activity in the logic model was to secure Medicaid status or ascertain 
funding for XR-NTX.  The Patient Centered Affordable Care Act of 2010 made a legal 
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requirement that substance abuse treatment is covered by state Medicaid and other insurance 
plans available through the Health Insurance Exchange by 2014 (Office of National Drug 
Control Policy, n.d.).  The 2015 Medicaid expansion in Alaska has increased access to substance 
abuse treatment including MAT for opioid or alcohol addiction.  Those released from 
incarceration often return to their community without employment or medical insurance 
coverage.  Thus, immediately upon release, most released prisoners are Medicaid eligible.  
Through education focusing on creating a fiscally sustainable project, applying for Medicaid is 
now a day of release priority for Partners Reentry Center.  Partners Reentry Center has limited 
funds available to cover costs related to the initial screening and administration of XR-NTX until 
Medicaid coverage is received.   
Securing samples.  The fourth activity in project’s logic model was securing samples of 
XR-NTX to keep project costs low.  Alkermes generously offered to provide samples of XR-
NTX to support its use within the Alaska Department of Corrections (ADOC).  These samples 
were distributed by Alkermes to willing providers.  
Modeling and enablement.  Modeling and enablement are additional interventions from 
the Behaviour Change Wheel that aided the progression of this project.  Information from 
Department of Correction programs from other states utilizing XR-NTX was presented to the 
ADOC for their review to generate interest regarding early access to XR-NTX.  Other programs 
found that implementing XR-NTX before release from incarceration showed a reduction in the 
risk of recidivism (Florida Alcohol & Drug Abuse Association, 2015; Miller, 2013).  ADOC 
expressed interest in exploring a pilot program for education, screening, and administration of 
XR-NTX in the halfway houses in Anchorage.  The proposed onset for this program is 
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November 2016.  ADOC also agreed to continue to explore the possibility of administering XR-
NTX before releasing from incarceration.  
Barriers and Challenges to Implementation 
This project sought to increase access to MAT with XR-NTX for a vulnerable population 
of recently released prisoners who battle addiction and opioid or alcohol abuse.  Only giving the 
medication XR-NTX is insufficient to treat addiction entirely, but it is a safety net.  Various 
reasons for declining XR-NTX are the initial barrier to implementing XR-NTX upon release 
from incarceration.  The invasive nature of an injection and the inconvenience of taking the time 
to seek medical care were significant barriers.  Regardless of insurance coverage, the cost of XR-
NTX will remain a barrier as sample medication will not necessarily be available long term.  A 
cost-benefit analysis of XR-NTX may show a sustainable program despite its high cost.  
 Development of a streamlined referral process from PRC was another barrier to 
overcome.  It was essential to create a referral process from Partners Reentry Center to 
community healthcare providers that met the guidelines of patient privacy according to the 
Health Insurance Portability and Accountability Act of 1996.  Providers and support staff 
required education and needed to experience positive outcomes to realize the importance of this 
project and create “buy-in” to provide a high level of support and care at the clinical level.  One 
of the major barriers was recalling participants for the next due injection of XR-NTX.  The onus 
of tracking and follow-up injections seemed to primarily fall on the medical provider despite the 
involvement of probation officers.  Maintaining an accurate log and having support staff actively 
recall and engage individuals to return for follow-up injections proved worrisome and time-
consuming.   
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 While on probation, urine drug screens are often required for those with a history of 
substance abuse.  Through board meetings held by Partners for Progress in Anchorage, probation 
officers were educated regarding the full opioid antagonist property of XR-NTX.  For those who 
received XR-NTX and failed a urine drug screen for opioids, it was recommended by Partners 
Reentry Center that increased support rather than a return to incarceration was the best approach.  
This approach has become increasingly accepted. 
Conclusion 
 Implementation of this project began September 15, 2015.  Although data collection 
ended September 15, 2016, those released from incarceration continue to be offered XR-NTX if 
they receive services and referral for XR-NTX from Partners Reentry Center.  Most individuals 
who accepted XR-NTX during this project were able to receive Alaska Medicaid eligibility by 
the second or third XR-NTX injection, thus reducing the strain on valuable funding resources 
and medication samples.  Clinical staff members involved were educated on screening and 
implementation of XR-NTX in the clinic setting and quickly became comfortable with the 
screening, injection, and patient tracking process.  All involved in the implementation of this 
project became experts on the use of XR-NTX and the importance of a strong support system to 
ensure community success of the released prisoner. 
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Chapter VI:  Evaluation of Project Outcomes 
 This overall aim of this project was to implement existing evidence-based medicine and 
improve health outcomes.  Access to extended-release injectable naltrexone (XR-NTX) was 
offered to recently released prisoners who received services to facilitate their community reentry 
at Partners Reentry Center (PRC) in Anchorage, Alaska.  Retrospective data provided by PRC 
from September 15, 2015, to September 15, 2016 was evaluated.  The outcomes of this project 
were very promising.   
Outcome Measures 
 Outcome measures listed on this project’s Logic Model (Appendix B) were utilized to 
determine the success of implementing this evidence-based practice initiative.  Recently released 
prisoners presenting to PRC were offered XR-NTX throughout the full year of this collaboration.  
Retrospective anonymous data was used to determine how many individuals accepted or 
declined XR-NTX.  Rates of recidivism were also determined for the entire group population 
during the one-year time frame of this project.  Recidivism rates were evaluated at the end of the 
one-year project for those who accepted XR-NTX in the first six months of the project.  
Demographic data was assessed.  The data provided by PRC included information for most 
individuals regarding support measures to assist with housing, employment, and behavioral 
counseling.  The effects of this additional support were evaluated.  
Data Analysis and Results 
 PRC offered XR-NTX to 98 recently released prisoners who self-identified as having a 
history of alcohol or opioid misuse during the time frame of this project.  Of these, 62% (n = 61) 
were male, 35% (n = 34) were female, and gender was unknown for 3% (n = 3).  Figure 6.1 
illustrates the distribution of the population by ethnicity, with 53% Caucasian, 31% Alaska 
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Native, and 16% other.  Figure 6.2 illustrates the distribution by age, with 49% (n = 48) of 
participants age 30 to 39.   
 
Figure 6.1.  Distribution of project participants by ethnicity. 
 
Figure 6.2.  Distribution of project participants by age. 
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Data was collected for 12 months on PRC participants.  It is not reliable to report 
recidivism rates on individuals who accepted XR-NTX in the final months.  Those who accepted 
on the final day of data collection would not have had adequate time to show effectiveness of 
receiving XR-NTX.  Ideally, this data will be followed longitudinally for comparison with 
known three-year recidivism rates.  During the first six months, 53% of the total participants had 
been offered XR-NTX as part of their post-incarceration release plan.  Figure 6.3 and Table 6.1 
show the comparison of recidivism rates between those who accepted and those who refused 
XR-NTX, with 38% versus 95% recidivating six or more months after receiving one or more 
injections of XR-NTX.  Results of the Chi-Square Test for Goodness and Fit of Association in 
showed a significant reduction in recidivism at 12 months for those who accepted XR-NTX 
during the first six months of data collection, χ2(1, N = 52) = 16.9, p = < .001.   
 
Figure 6.3. Recidivism rates at 12-months for participants enrolled during first six months. 
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Table 6.1  
A Comparison of Recidivism Rates at 12 Months Between Those Accepting and Refusing XR-
NTX in First Six Months of Project Implementation 
 
 Additional measures to reduce recidivism.  Although not identified as outcomes in the 
development of this project work, PRC offered important data regarding the prevalence of 
housing, employment, and participation in behavioral health counseling for their participants.  It 
was explored whether these variables had an additional or independent impact on recidivism 
rates in comparison to the overall rates of recidivism for those who accepted or refused XR-
NTX.  Figure 6.4 depicts those who accepted XR-NTX (n = 60) along with housing, 
employment, behavioral counseling, or all three.  The results showed negligible change in 
recidivism.  This lack of change in recidivism may be related to the short-term follow-up of 
participants.  Also of interest, of those who refused XR-NTX yet had employment (n = 12), 67% 
recidivated versus 87% for the entire population that refused XR-NTX (n = 38).  Additional 
participants will be needed to create a large enough population to evaluate statistical significance 
with regard to these outcomes.  
 
Accepted Refused Total
      No 20           1             21           
      Yes 12           19           31           
Total 32           20           52           
Recidivated
XR-NTX >= 6 month
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Figure 6.4.  Comparison of Recidivism Rates Among Project Participants Who Accepted or 
Refused XR-NTX and Had Additional Support Measures. 
Another comparison was made between those who accepted XR-NTX and had no 
additional support measures.  It was interesting to see that recidivism rates did not vary much 
between the groups who had support as shown in Figure 6.4 and those who did not have 
additional support services as illustrated in Figure 6.5.  Again, the number of individuals in each 
category was not large enough to show a statistically meaningful correlation.  Although it may 
seem obvious, Figure 6.5 also shows that doing nothing leads to nearly 100% recidivism.  
 
Figure 6.5. Comparison of Recidivism Rates Among Project Participants Who Accepted or 
Refused XR-NTX and Had No Additional Support Measures.  
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Discussion of Results 
  Using XR-NTX in the released prisoner population through collaboration between PRC 
and community-based primary care providers in Anchorage, Alaska showed a statistically 
significant reduction in recidivism in those who accepted XR-NTX in their post-release plan.  
Only one person who refused XR-NTX remained in their community at greater than six months 
compared to 20 individuals who received XR-NTX and did not recidivate.  The daily rate of a 
hard bed in the Alaska prison system costs $158 a day (Guiterrez, 2015).  The reduction in 
recidivism due to XR-NTX if these 20 individuals stay in their community for a full year will 
save the State of Alaska over $1 million.  The implementation of early access to XR-NTX upon 
release from incarceration proved an important application of evidence-based practice. 
Limitations.  There were limitations to this retrospective evidence-based practice 
implementation project.  In general, evidence-based practice outcomes in a community are not 
generalizable to other populations (Melnyk & Fineout-Overholt, 2015).  The number of people in 
this project was too small to evaluate the independent effects of other variables that affect 
recidivism, although emerging trends were seen providing a recommendation for future research.  
PRC stated it was difficult to obtain and track data on this population.  Specifically, to document 
how many injections of XR-NTX each participant received.  Self-selection bias is also a 
limitation to the generalizability of this data as those who opted to utilize XR-NTX may have 
been highly motivated and less likely to recidivate overall in comparison to those who did not 
accept XR-NTX.  Following this data over three years will allow for comparison to the ADOC 
2011 three-year recidivism rate of 63% (Gutierrez, 2015).   
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Conclusion 
The use of XR-NTX is a substance abuse treatment that follows evidenced-based 
medicine.  The American Society of Addiction Medicine national practice guideline recommends 
using Medication-Assisted Treatment, such as XR-NTX, in alcohol and opioid abuse treatment 
(2015).  The data in this project should be followed longitudinally to meet the other project 
outcome of comparing present and long-term criminal recidivism rates with acceptance or refusal 
of XR-NTX.  Other data provided to this project leader regarding employment, housing, and 
behavioral counseling could be useful in planning future programs that would ensure the best 
community success for the released prisoner if followed over time.  
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 Chapter VII:  Implications for Nursing Practice 
Advanced nursing degrees will be at the forefront of changes in healthcare in the United 
States.  In 2008 the Institute of Medicine (IOM) and the Robert Wood Johnson Foundation 
collaborated to examine nursing and its potential contribution to meet the challenges brought 
forth by a call for health care reform that would improve healthcare outcomes and reduce 
healthcare expenditure (Institute of Medicine [IOM], 2011).  The document “The Future of 
Nursing: Leading Change, Advancing Health” (IOM, 2011) calls upon nurses to move into 
leadership roles to influence healthcare outcomes and policy change.  The IOM cites a Gallup 
Poll from 2010 “Nursing Leadership from Bedside to Boardroom: Opinion Leaders’ 
Perceptions” which suggests that while nurses are trusted health professionals, they are not yet 
viewed as capable of improving access to healthcare, influencing reform, or having a strong 
voice in the realm of health policy.  The IOM calls upon nursing to make changes to this 
perception and reality.  The evolution of the Doctorate of Nursing Practice (DNP) degree will 
help this transformation to nurses as leaders in the health care community. 
Essentials of Doctoral Education for Advanced Nursing Practice  
In October 2006, the American Association of Colleges of Nursing (AACN) published 
the eight essentials for nursing practice to attain in the DNP degree program.   
Essential I:  Scientific underpinnings for practice.  The first essential of the DNP 
degree strives to “Integrate nursing science with knowledge from ethics, the biophysical, 
psychosocial, analytical, and organizational sciences as the basis for the highest level of nursing 
practice” (AACN, 2006, p. 10).  This project utilized scientific evidence-based medicine to 
improve healthcare by providing access to extended-release injectable naltrexone (XR-NTX) to 
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an underserved population by collaborating with other community stakeholders working with 
released prisoners.  
Essential II:  Organizational and systems leadership for quality improvement and 
systems thinking.  This area of competency is meant to improve patient outcomes beyond the 
DNP student's current practice setting with a goal to improve health for a larger population 
within the community by creating a plan to implement a healthcare initiative, and working with 
other organizations to facilitate this improvement (AACN, 2006).  A primary care family nurse 
practitioner would not typically work directly with individuals immediately released from 
incarceration.  However, there was an opportunity to provide these people with access to XR-
NTX upon release, which was a medical treatment not readily accessible.  Meeting with the non-
profit group, Partners Reentry Center (PRC), in September 2015 helped identify issues leading to 
recidivism.  Brainstorming was conducted to find ways to overcome this barrier and ease access 
to XR-NTX to aid the success of the released prisoner in their community.  Attending bi-monthly 
board meetings at PRC helped provide the overall picture of reducing recidivism while ensuring 
the project was financially sustainable. 
Essential III:  Clinical scholarship and analytical methods for evidence-based 
practice.  This essential embodies the process of nursing research (AACN, 2006).  This project 
started due to a perceived need to reduce substance-related crime and recidivism.  A literature 
review was conducted to evaluate existing research surrounding the use of XR-NTX to prevent 
recidivism.  The body of evidence is still emerging in regards to this topic.  The data from this 
project show that XR-NTX is a promising tool to help prevent recidivism for those who are 
highly motivated to receive the monthly injection.  The data from this ongoing project have been 
disseminated to various healthcare care clinicians in the Anchorage community, substance abuse 
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treatment programs, and to the Alaska Nurse Practitioner’s Association annual conference.  It is 
important to have widespread dissemination of this important nursing evidence-based project 
work, especially given the limited body of published research in regards to the use of XR-NTX 
and its potential for recidivism reduction.  
Essential IV:  Information systems/technology and patient care technology for the 
improvement and transformation of healthcare.  The use of technology for this project was 
limited to the data collection process that was conducted by PRC.  The prisoner population is a 
considered a vulnerable population according to the Institutional Review Board.  Thus data 
provided for the purpose of this project had to be de-identified to ensure confidentiality (U.S. 
Department of Health and Human Services Office for Human Research Protections, 2003).  
Mentoring from the project leader was required to guide what data was needed to provide 
meaningful project outcomes.  At the end of this project, suggestions were made for future data 
collection and ongoing research possibilities.  A referral process was created from PRC to 
community healthcare providers that met the guidelines of patient privacy according to the 
Health Insurance Portability and Accountability Act of 1996.  Also, providers administering XR-
NTX should utilize the electronic health record system to schedule patients for four-week 
follow-up appointments for future XR-NTX injections or use the electronic health record to set 
reminders to contact patients receiving XR-NTX before the due date of their next dose.   
Essential V:  Health care policy and advocacy in healthcare.  According to the AACN 
“the DNP graduate is able to design, implement and advocate for health care policy that 
addresses issues of social justice and equity in health care” (2006, p. 14).  Using a theoretical 
model of care, the Behavioural Change Wheel (Appendix C), allowed for a systematic approach 
to implementing a healthcare initiative to advocate for a change in health policy (Michie, van 
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Stralen, & West, 2011).  The Alaska Department of Corrections (ADOC) is now considering the 
use of XR-NTX in halfway housing with implementation set to occur in November, 2016.  
Several meetings with the medical director from the ADOC facilitated the development of a draft 
policy for future screening and administration of XR-NTX.   
Essential VI:  Interprofessional collaboration for improving patient and population 
health outcomes.  This essential highlights the importance of collaboration between professional 
entities to truly improve population health (AACN, 2006).  The Interprofessional Education 
Collaborative Expert Panel states “The goal of this interprofessional learning is to prepare all 
health professions students for deliberatively working together with the common goal of 
building a safer and better patient-centered and community/population-oriented U.S. health care 
system” (2011, p. 3).  It was a meaningful experience to draw on the expertise of numerous 
professionals to solve a public health problem and reduce recidivism.   
Essential VII:  Clinical prevention and population health for improving the nation’s 
health.  This project clearly meets this DNP essential that brings focus to the importance of 
preventing adverse health outcomes and improving population health regardless of culture or 
socioeconomic variables (AACN, 2006).  XR-NTX provides a safety net to prevent relapse of 
opioid or alcohol use, which in turn prevented recidivism.  Although treatment with XR-NTX is 
costly, all participants in this project were eligible regardless of insurance or ability to pay and 
thus eliminated gaps in their capacity to receive care.  Perhaps most important of all, those 
involved in this project were able to view addiction as a disease state that was not a reflection of 
personal choice.  
Essential VIII:  Advanced nursing practice.  The DNP degree promotes specialization 
within the advanced nursing practice.  Throughout the DNP project, there is an opportunity to 
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become a nurse leader and expert on a particular topic, thus becoming a community expert and 
resource (AACN, 2006).  This level of leadership has the power to change health care for the 
patient up to the systems level of healthcare delivery while utilizing a strong nursing 
background.  Implementing this project offering early access to XR-NTX upon release from 
incarceration required a high degree of healthcare ethics and cultural awareness to work with a 
vulnerable population.  Existing literature was reviewed and utilized as a basis for implementing 
a comprehensive program that would improve health outcomes through an interprofessional 
approach.  This project fully realized the importance of building professional relationships and 
using the strengths of others.  This project will serve as a basis for additional nursing projects on 
alcohol and opioid misuse.  Seeing policy changes emerge within the ADOC based on the data 
from this project is the culmination of the efforts in this project.  
Implications 
The 2015 National Drug Control Strategy (Office of National Drug Control Policy, 2015) 
states substance misuse is a medical disorder that is preventable and treatable, much like any 
other illness.  MAT is underutilized, mainly due to lack of knowledge regarding medication 
options and their benefit in the treatment of addicts (National Association of Drug Court 
Professionals, 2013).  Nursing leadership is well suited to implement an evidence-based project 
to improve population health in their community.  The data from this project providing early 
access to XR-NTX upon release from incarceration shows the immense power of implementing 
evidence-based practice through community collaboration to improve population health.   
Positive health outcomes are also more cost effective.  The Institute for Healthcare 
Improvement (IHI) (2016) discusses a triple aim approach at improving healthcare:  Improve 
population health, improve the patient experience in healthcare, and reduce per capita 
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expenditure on healthcare.  The IHI states that all three dimensions need to be simultaneously 
considered to achieve notable improvement in healthcare in the United States.  When considering 
the implementation of an evidence-based guideline into the practice setting, it is critical to 
recognize the value of the guideline in regards to safety, improved patient outcomes, and patient 
satisfaction, all while maintaining a cost that is reasonable (Anderson et al., 2014).  The use of 
XR-NTX in the released prisoner population has potential cost-saving benefit to the State of 
Alaska.  
Barriers to Implementation 
Implementing early access to XR-NTX upon release from incarceration required 
extensive collaboration between PRC and various community healthcare providers.  This 
collaborative process was not without challenges.  One primary care facility that patients are 
referred to has a policy that requires a one-month trial and failure of oral naltrexone before 
administration of XR-NTX.  This system is, of course, counterintuitive to the goals of this 
project.  Patients who typically received care at this facility received a referral to another primary 
care facility in town that did not have this stipulation for use.  Another challenge encountered 
was transportation to the primary care provider offices.  While many facilities are on the bus 
routes, the connections were not convenient and thus created a barrier to receiving the first 
injection of XR-NTX.  When necessary, PRC opted to send individuals in a paid taxi using their 
grant funds.  A future solution will be the upcoming opening of a primary care facility nearer to 
downtown Anchorage, which will improve access to care.   
As more individuals seek XR-NTX in their treatment and release plan, another barrier is 
the general lack of primary care providers who have received education on substance abuse and 
the use of XR-NTX.  Hopefully, more primary care providers become interested in screening and 
REDUCING RECIDIVISM IN ALASKA 70 
 
treatment for substance abuse, and outreach is ongoing to community providers interested in or 
involved in drug or alcohol misuse.  
Procuring samples and ensuring their availability was intermittently a challenge to 
providing care and optimizing this project.  Those working with released prisoners now place 
greater emphasis on applying early for Alaska State Medicaid eligibility.  Without insurance 
coverage, the cost of XR-NTX is certainly a barrier.  However, expansion of Alaska Medicaid 
eligibility significantly increased access to substance abuse treatment, and many of those 
previously incarcerated qualify for Medicaid benefits upon release.  The costs associated with 
implementing this pilot program would be far less that daily cost of incarceration, which was 
$158.67 in 2014 (Gutierrez, 2015).   
Historically, XR-NTX is not recommended as a stand-alone treatment for opioid or 
alcohol abuse.  It works in conjunction with a comprehensive substance abuse program.  Gaining 
access to evidence-based substance abuse treatment programs remains an ongoing barrier in the 
State of Alaska because there are not enough behavioral health resources to meet the demands.  
The Affordable Care Act requires the coverage of substance abuse treatment as a benefit 
provided by insurance policies ascertained through the Health Insurance Exchange or State 
Medicaid (Office of National Drug Control Policy, n.d.).  However, providers often limit access 
to care for those underinsured with Alaska State Medicaid or Medicare insurance policies.  PRC 
has increased their efforts in providing Moral Reconation Therapy and Peer-To-Peer groups as a 
means to provide a substance abuse program for recently released prisoners.  Local 12-step 
programs through Narcotics Anonymous and Alcoholics Anonymous are another free option.  
There may be future grant funding available to facilitate behavioral health services in 
collaboration with other community partners.  
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Conclusion 
Nurses and nurse practitioners are often on the frontline of patient care.  A quality 
improvement initiative will be successful with strong leadership to influence change.  Initiating 
early access to XR-NTX requires more healthcare providers who are willing to screen and utilize 
medically assisted treatment to aid in the treatment of alcohol or opioid abuse.  With the 
assistance of PRC and other existing and new community partners, this project will drive change 
to reduce barriers and create solutions to implementing early access to XR-NTX with a long-
term goal to reduce recidivism.  This initiative will drive funding and policy change to further 
efforts towards access to XR-NTX.  This project clearly addresses all of the Essentials for the 
Doctor of Nursing Practice degree.  
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Chapter VIII:  Summary and Conclusion 
Alaska’s Department of Corrections (ADOC) facilities are at capacity, with an 11% 
growth expected by 2018 (Gutierrez, 2015).  Published after the onset of this project, the Alaska 
Criminal Justice Commission’s 2015 Justice Reinvestment Report includes 21 recommendations 
for reducing the ADOC’s prisoner population by 2024 (Coghill, 2016).  The 21 
recommendations will: “implement evidence-based pretrial practices; focus prison beds on 
serious and violent offenders; strengthen supervision and interventions to reduce recidivism; 
ensure oversight and accountability; and advance crime victim priorities” (Alaska Criminal 
Justice Commission, 2015).  The Justice Reinvestment Report became the basis for Alaska 
Senate Bill (SB) 91 (2015-2016), which aims to reform criminal justice, improve public safety, 
and save an estimated $380 million dollars over the next decade (Coghill, 2016).  During the 
course of this project implementation, SB 91 passed on April 9, 2016, with a 16-2 vote.  This 
important legislation will lead the way for sentencing and parole reform and improving services 
upon release from prison to prevent recidivism.   
Public health policy can change population health.  The adoption of health policies 
shapes the allocation of funding which allows for successful implementation of a proposed 
program (Centers for Disease Control and Prevention [CDC], 2015b).  On February 2, 2016, 
President Obama proposed $1.1 billion in spending beginning in the FY2017 budget to address 
our nation’s drug epidemic.  The goal of the funding is to improve access to treatment for 
substance abuse across the nation through the use of medication-assisted treatment (MAT) to 
combat a growing epidemic of opioid and heroin abuse (The White House, 2016b).  This funding 
will hopefully heighten the awareness and utilization of MAT throughout the nation.  
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A high percentage of those incarcerated in the ADOC are directly due to alcohol 
(12.32%) and drugs (12.16%) (Alaska Department of Corrections, 2015).  Providing access to 
extended-release injectable naltrexone (XR-NTX) upon release from incarceration has proved an 
important measure in reducing recidivism in the State of Alaska.  
Key Points 
 This project has proved a very timely topic as rates of opioid use are soaring, and rates of 
alcohol misuse in the State of Alaska remains high.  Heroin addiction has doubled in the past 
decade and is an epidemic (CDC, 2015a), yet alcohol remains the most widely used and abused 
drug in the United States and is the third leading lifestyle-related cause of death in the U.S. (State 
of Alaska, 2015a).  The U.S. Surgeon General, Vivek Murthy, has created the “Turn the Tide 
Rx” movement to reduce the opioid crisis in the U.S.  All healthcare providers are asked to sign a 
pledge to help combat this growing epidemic through safe opioid prescribing (Surgeon General 
of the United States, n.d.).  
MAT remains vastly underutilized as an adjunct in substance abuse treatment.  Only one 
out of 10 substance-addicted individuals (excluding nicotine) receives any treatment at all 
(CASAColumbia, 2010).  Although there is not a “one size fits all” in healthcare, this project 
shows that using MAT, specifically XR-NTX, is a valuable support tool in the recovery from 
substance or alcohol addiction.  The outcomes from this project have aided the task of educating 
community providers about the potential of using XR-NTX in recovery from substance and 
alcohol abuse as it promotes abstinence while working through a formal treatment program.  
Healthcare professionals at the front lines of treatment are in a prime position to screen for 
substance abuse history and begin the conversation about treatment options.  Education of the 
patient diagnosed with substance abuse is also imperative as they may lack knowledge of the 
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available treatment options.  Knowledge is the key to implementing changes in healthcare 
practice.   
Providing access to XR-NTX upon release from incarceration with a goal to reduce 
recidivism seemed a simple task at the outset.  However, building collaborative relationships 
with all involved in prisoner release was the hallmark of this project.  The significant reduction 
in recidivism demonstrated in this project shows the strength of community collaboration.     
Conclusion 
Along with comprehensive community resources to help the released prisoner 
successfully reenter their community, XR-NTX may be one tool to reduce recidivism and the 
burden on ADOC facilities.  The ADOC, those previously incarcerated with substance abuse, 
and Alaska’s communities would be well-served to continue this collaborative project.  Another 
goal would be to initiate a program that focuses on the use of XR-NTX before prisoners are 
released from incarceration to further reduce the risk of recidivism due to immediate alcohol or 
opioid misuse upon release.  Beyond monetary savings, XR-NTX has the potential to contribute 
to reducing deaths related to opioid overdose, reduce crime in the community, and improve the 
lives of those with a history of substance or alcohol misuse.  President Obama aptly proclaimed 
“during Prescription Opioid and Heroin Epidemic Awareness Week, we pause to remember all 
those we have lost to opioid use disorder, we stand with the courageous individuals in recovery, 
and we recognize the importance of raising awareness of this epidemic” (The White House, 
2016a). 
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Appendix B  
Logic Model Early Access Extended-Release Injectable Naltrexone (XR-NTX) 
 
Assumptions:  
(1) Recidivism affects our community, and partnerships formed within our community will 
help improve recidivism.  
(2) Expanding Medicaid in the State of Alaska will improve access to care and substance 
abuse treatment. 
(3) Shifting revenues to provide for early access to XR-NTX will improve health outcomes 
and reduce recidivism. 
(4) Our community can unite to shape policy at local and state levels as it pertains to 
recidivism. 
Vision and mission:  Facilitate early access to XR-NTX for returning offenders while educating 
healthcare providers about the use of XR-NTX to aid substance abuse treatment. 
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Behavioural Change Wheel 
 
Michie, S., van Stralen, M. M., & West, R. (2011). The behaviour change wheel: A new method 
for characterising and designing behaviour change interventions. Implementation Science : IS, 6, 
42. http://doi.org/10.1186/1748-5908-6-42 
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Appendix D  
Partners for Progress Letter of Support 
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Appendix E 
IRB Determination Letter 
 
INSTITUTIONAL REVIEW BOARD REQUEST FOR DETERMINATION OF HUMAN 
SUBJECTS RESEARCH  
  
   
All research conducted by University of Alaska Anchorage faculty, staff, or students, which 
involves human subjects must be reviewed by the Institutional Review Board (IRB).  To 
determine if your project involves human subjects or is research under UAA IRB definitions, 
complete this form and send it to the UAA Research Compliance Officer, 
simumaw@uaa.alaska.edu.  For help, contact the Office of Research Integrity & Compliance 
(ORIC): (907) 786-1099.  
   
Consider your activity (research project, thesis, study, task, assignment) and the data 
(information) you, a member of your research team, or a collaborator, plan to collect, when 
responding to these questions.  
Activity Examples: surveys, questionnaires, focus groups, interviews   passive observation of 
public behavior (in physical or online environments, including social media)   experiments using 
electronic equipment or gaming techniques   the use of instruments or devices, including phones, 
to collect or monitor or influence behavior   diet, nutrition studies, or taste tests   physical or 
biomedical procedures, such as imaging, scanning, blood collection, anthropomorphic 
procedures   studies examining individuals’ responses to manipulation of their physical or online 
environment   studies examining effectiveness of educational tools or curricula   pilot studies and 
other preliminary studies   any other activity that involves observation of, or interaction with, 
individuals to gather information for research.  
Enter a response for each question, complete Section B on Page 2 and send to  
simumaw@uaa.alaska.edu  Yes/No Not sure  
Is all of the data (information) being obtained about deceased people? (If No, skip the next 
question and go to RD1)    NO  
In addition to information about the deceased people, are you also collecting information from 
living persons about their recollections of the deceased people? (If No, stop here and go to RD 2) 
   
RD1)  Does your project only involve existing data, information, documents, or samples that you 
will obtain from a publicly available source that does not require permission to access the data? 
(If Yes, stop here and go to RD2.)    NO  
Does a funding source (federal, state, or local), either directly (direct funder) or indirectly 
(secondary, or pass-through funder) require IRB review? (If Yes, stop here and go to RD3)    
NO  
  
Is any of the data (information) being obtained about individuals who are, or could be, living 
now?    NO  
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Is any of the data (information) being obtained, directly or indirectly, from living individuals?    
NO  
  
Are you observing people, directly or indirectly, to collect your information?    NO   
  
Are you interacting (face-to-face, through telephone, electronic media or documents) with 
people?    NO  
Is the data collected by intervening (taking measurements, samples, images) with people, or 
observing an intervention carried out by another person?    NO  
Does the data/information you are collecting only center on things, quantities, or other questions 
about what item, process, or procedure is used? (If Yes, stop here and go to RD2)  YES  
  
Does the data/information you are collecting include the opinions, characteristics, or behavior of 
individuals?     
  
Does the data/information you are collecting include any information that could identify the 
individuals?     
  
Does the data/information you are using to recruit people for your project include any 
information that could identify the individual?     
  
During the process of collecting data, will you or any research team member, be able to identify 
the individuals?     
Will the data or information you are collecting examine, for example, the function of culture, 
expression of gender, or political views of members of the population in the study?     
  
Could the results of this evaluation be used to make a general conclusion about the 
data/information you will collect?      
  
Is this evaluation connected to individual or group outcomes?      
  
Could the results of this evaluation impact the future use of similar programs, services, or public 
policy?     
  
Can this evaluation affect the development or implementation of other programs of a similar 
nature?     
   
INSTITUTIONAL REVIEW BOARD REQUEST FOR DETERMINATION OF HUMAN 
SUBJECTS RESEARCH  
  
If you answered Not Sure for any question, briefly explain why you are uncertain.  
This project is about implementing access to the injectable medication Vivitrol (XR-NTX) for 
recently released prisoners.  We are  
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evaluating the success of XR-NTX in reducing recidivism in Alaska. There is no focus on the 
individual receiving the medication.   Participants self-selected to receive XR-NTX as part of 
their treatment program and community re-entry post incarceration.   
RD2 – Your work is most likely not human subject research and you do not need to complete the 
rest of the first section. Complete Section B and return the Request for IRB Determination form 
for a final confirmation.  
RD3 – Your work must be reviewed by the IRB. Go to IRBNet and complete a UAA IRB 
Proposal and all additional documents for IRB review.  
  
Section B – Instructions, tab to each box and complete the information.  
  
Name:  Jyll Green             Today’s Date:  February 19, 2016  
  
Affiliation with UAA (If this project will be used for class credit, complete the next two lines. If 
not, skip to Faculty/Staff):  
  
Student Level:  Choose an item.DNP -FNP   Course Number: Subject-CourseND A696a   
  
 Faculty Advisor:     Department:  
 Dr. Lisa Jackson  School of Nursing  
  
 Faculty ܆ or  Staff ܆  College or School:  University of Alaska Anchorage Enter here 
 Department:Enter here    
  
   Center, Program, or Institute: Click here to enter.  
    
Project Title: Reducing Recidivism in Alaska through Access to Extended-Release Injectable 
Naltrexone. Reducing  




Naltrexone         
  
  
Project Description:  This Quality Improvement/Access to Care initiative will facilitate early 
access to XR-NTX for returning prisoners by educating healthcare providers about the use of 
XR-NTX to aid substance abuse treatment.  The goal is to reduce the rate of recidivism in 
Alaska.  Partners for Progress (PFP) including therapeutic courts and Partners Reentry Center, 
their clients, and local primary care providers all contribute to the effort of the initiative.   
Increasing the number of sites willing to administer XR-NTX on an urgent basis, along with the 
number of offenders who chose to receive XR-NTX and do not recidivate, will show success of 
this program.  Retrospective de-identified aggregate data will be provided by Partners for 
Progress to the project manager including: percentage of offenders who accepted XR-NTX, 
percentage of offenders who did not accept XR-NTX, percentage of offenders who recidivated 
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and accepted XR-NTX, percentage of offenders who recidivated and did not accept XR-NTX. 
Using the aggregate data obtained through PFP, the effectiveness of the initiative to facilitate 
early access to XR-NTX and the reduction in recidivism can be measured.  Although recently 
released prisoners is a  vulnerable population, only aggregate data will be evaluated.  Education 
and treatment of alcohol and drug addiction is within the scope of the project manager’s 
professional practice.     
  
Population:  Recently released prisoners who elected to receive XR-NTX or declined.   
Plan:  I will not be interacting directly with any participants on whom data has been collected by 
a third party, Partners for Progress.   
Partners will be providing de-identified group statistics to evaluate the effectiveness of 
implementing early access to XR-NTX upon release from incarceration and its effects on 




For Office of Research Integrity & Compliance Use Only  
  
Final Determination:  HSR  Not HSR  
  
Statement of Findings:   What questions, not whom questions, analysis of rate changes pre & 
post training.   
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Appendix F   
XR-NTX Patient Counseling Checklist 
 PATIENT COUNSELING 
INFORMATION 
Physicians should include the following issues in discussions with patients for whom they prescribe 
VIVITROL. Please ensure that each patient is given a copy of the FDA-Approved Medication Guide:  
  
 Advise patients that if they previously used opioids, they may be more sensitive to lower doses of opioids 
and at risk of accidental overdose should they use opioids when their next dose is due, if they miss a dose, or 
after VIVITROL treatment is discontinued. It is important that patients inform family members and the 
people closest to the patient of this increased sensitivity to opioids and the risk of overdose. 
 Advise patients that because VIVITROL can block the effects of opioids, patients will not perceive any 
effect if they attempt to self-administer heroin or any other opioid drug in small doses while on VIVITROL. 
Further, emphasize that administration of large doses of heroin or any other opioid to try to bypass the 
blockade and get high while on VIVITROL may lead to serious injury, coma, or death. 
 Patients on VIVITROL may not experience the expected effects from opioid-containing analgesic, 
antidiarrheal, or antitussive medications. 
 Advise patients that a reaction at the site of VIVITROL injection may occur. Reactions include pain, 
tenderness, induration, swelling, erythema, bruising, or pruritus. Serious injection site reactions including 
necrosis may occur. Some of these injection site reactions have required surgery. Patients should receive 
their injection from a healthcare provider qualified to administer the injection. Patients should be advised to 
seek medical attention for worsening skin reactions. 
 Advise patients that they should be off all opioids, including opioid-containing medicines, for a minimum of 
7 – 10 days before starting VIVITROL in order to avoid precipitation of opioid withdrawal. Patients 
transitioning from buprenorphine or methadone may be vulnerable to precipitation of withdrawal 
symptoms for as long as two weeks. Ensure that patients understand that withdrawal precipitated by 
administration of an opioid antagonist may be severe enough to require hospitalization if they have not 
been opioid-free for an adequate period of time, and is different from the experience of spontaneous 
withdrawal that occurs with discontinuation of opioid in a dependent individual. Advise patients that they 
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should not take VIVITROL if they have any symptoms of opioid withdrawal. Advise all patients, including 
those with alcohol dependence, that it is imperative to notify healthcare providers of any recent use of 
opioids or any history of opioid dependence before starting VIVITROL to avoid precipitation of opioid 
withdrawal. 
 Advise patients that VIVITROL may cause liver injury. Patients should immediately notify their physician if 
they develop symptoms and/or signs of liver disease. 
 Advise patients that they may experience depression while taking VIVITROL. It is important that patients 
inform family members and the people closest to the patient that they are taking VIVITROL and that they 
should call a doctor right away should they become depressed or experience symptoms of depression. 
 PATIENT COUNSELING 
INFORMATION 
 Advise patients to carry documentation to alert medical personnel to the fact that they are taking VIVITROL 
(naltrexone for extended-release injectable suspension). This will help to ensure that patients obtain 
adequate medical treatment in an emergency. 
 Advise patients that VIVITROL may cause an allergic pneumonia. Patients should immediately notify their 
physician if they develop signs and symptoms of pneumonia, including dyspnea, coughing, or wheezing. 
 Advise patients that they should not take VIVITROL if they are allergic to VIVITROL or any of the microsphere 
or diluent components. 
 Advise patients that they may experience nausea following the initial injection of VIVITROL. These episodes 
of nausea tend to be mild and subside within a few days post-injection. Patients are less likely to 
experience nausea in subsequent injections. Patients should be advised that they may also experience 
tiredness, headache, vomiting, decreased appetite, painful joints and muscle cramps. 
 Advise patients that because VIVITROL is an intramuscular injection and not an implanted device, once 
VIVITROL is injected, it is not possible to remove it from the body. 
 Advise patients that VIVITROL has been shown to treat alcohol and opioid dependence only when used as 
part of a treatment program that includes counseling and support. 
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 Advise patients that dizziness may occur with VIVITROL treatment, and they should avoid driving or 
operating heavy machinery until they have determined how VIVITROL affects them. 
 Advise patients to notify their physician if they: 
• become pregnant or intend to become pregnant during treatment with VIVITROL. 
• are breast-feeding. 
• experience respiratory symptoms such as dyspnea, coughing, or wheezing when taking VIVITROL. 
• experience any allergic reactions when taking VIVITROL. 
• experience other unusual or significant side effects while on VIVITROL therapy. 
 Patients should be advised of any other risks and information based on the clinical judgment of their physician. 
A patient wallet card or medical alert bracelet can be ordered from: 1-800-848-4876, Option #1. 
For more information, see the FDA-approved Prescribing Information and Medication Guide. 
IMPORTANT SAFETY INFORMATION FOR VIVITROL®  
(naltrexone for extended-release injectable suspension)  
 
INDICATIONS  
VIVITROL is indicated for:  
Treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting. Patients should not be actively drinking at the time of 
initial VIVITROL administration.  
Prevention of relapse to opioid dependence, following opioid detoxification.  
VIVITROL should be part of a comprehensive management program that includes psychosocial support. 
CONTRAINDICATIONS 
VIVITROL is contraindicated in patients: 
Receiving opioid analgesics  
With current physiologic opioid dependence  
In acute opioid withdrawal  
Who have failed the naloxone challenge test or have a positive urine screen for opioids  
Who have exhibited hypersensitivity to naltrexone, polylactide-co-glycolide (PLG), carboxymethylcellulose, or any other components of the diluent  
WARNINGS/PRECAUTIONS  
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Vulnerability to Opioid Overdose:  Because VIVITROL blocks the effects of exogenous opioids for approximately 28 days after administration, patients are likely to 
have a reduced tolerance to opioids after opioid detoxification. As the blockade dissipates, use of previously tolerated doses of opioids could result in potentially 
life-threatening opioid intoxication (respiratory compromise or arrest, circulatory collapse, etc). Cases of opioid overdose with fatal outcomes have been reported in 
patients who used opioids at the end of a dosing interval, after missing a scheduled dose, or after discontinuing treatment. Patients and caregivers should be told of 
this increased sensitivity to opioids and the risk of overdose.  
Any attempt by a patient to overcome the VIVITROL blockade by taking opioids may lead to fatal overdose. Patients should be told of the serious consequences of 
trying to overcome the opioid blockade. 
Injection Site Reactions:  VIVITROL injections may be followed by pain, tenderness, induration, swelling, erythema, bruising, or pruritus; however, in some cases 
injection site reactions may be very severe. Injection site reactions not improving may require prompt medical attention, including, in some cases, surgical 
intervention. Inadvertent subcutaneous/adipose layer injection of VIVITROL may increase the likelihood of severe injection site reactions. Select proper needle size 
for patient body habitus, and use only the needles provided in the carton. Patients should be informed that any concerning injection site reactions should be 
brought to the attention of their healthcare provider. 
Precipitation of Opioid Withdrawal:  Withdrawal precipitated by administration of VIVITROL may be severe. Some cases of withdrawal symptoms have been severe 
enough to require hospitalization and management in the ICU. To prevent precipitated withdrawal, patients, including those being treated for alcohol dependence:  
Should be opioid-free (including tramadol) for a minimum of 7–10 days before starting VIVITROL. 
Patients transitioning from buprenorphine or methadone may be vulnerable to precipitated withdrawal for as long as two weeks.  
Patients should be made aware of the risk associated with precipitated withdrawal and be encouraged to give an accurate account of last opioid use. 
Hepatotoxicity:  Cases of hepatitis and clinically significant liver dysfunction have been observed in association with VIVITROL. Warn patients of the risk of hepatic 
injury; advise them to seek help if experiencing symptoms of acute hepatitis. Discontinue use of VIVITROL in patients who exhibit acute hepatitis symptoms. 
Depression and Suicidality:  Alcohol- and opioid-dependent patients taking VIVITROL should be monitored for depression or suicidal thoughts. Alert families and 
caregivers to monitor and report the emergence of symptoms of depression or suicidality. 
When Reversal of VIVITROL Blockade is Required for Pain Management:  For VIVITROL patients in emergency situations, suggestions for pain management include 
regional analgesia or use of non-opioid analgesics. If opioid therapy is required to reverse the VIVITROL blockade, patients should be closely monitored by trained 
personnel in a setting staffed and equipped for CPR. 
Eosinophilic Pneumonia:  Cases of eosinophilic pneumonia requiring hospitalization have been reported. Warn patients of the risk of eosinophilic pneumonia and to 
seek medical attention if they develop symptoms of pneumonia. 
Hypersensitivity Reactions:  Patients should be warned of the risk of hypersensitivity reactions, including anaphylaxis. 
Intramuscular Injections:  As with any IM injection, VIVITROL should be administered with caution to patients with thrombocytopenia or any coagulation disorder. 
ADVERSE REACTIONS  
Serious adverse reactions that may be associated with VIVITROL therapy in clinical use include severe injection site reactions, eosinophilic pneumonia, serious 
allergic reactions, unintended precipitation of opioid withdrawal, accidental opioid overdose, and depression and suicidality. The adverse events seen most 
frequently in association with VIVITROL therapy for alcohol dependence include nausea, vomiting, injection site reactions (including induration, pruritus, nodules, 
and swelling), muscle cramps, dizziness or syncope, somnolence or sedation, anorexia, decreased appetite or other appetite disorders. The adverse events seen 
most frequently in association with VIVITROL in opioid-dependent patients also include hepatic enzyme abnormalities, injection site pain, nasopharyngitis, insomnia, 
and toothache. 
Please see Prescribing Information, including Medication Guide. Review the Medication Guide with your patient. 




Alkermes. (2016). Patient counseling information. Retrieved from 
https://www.vivitrol.com/HCP/VivitrolResources/PatientCounselingChecklist 
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Appendix G 
NIDA Quick Screen V1.0/ NIDA-Modified ASSIST V2.0 
NIDA Quick Screen V1.0F 1 
 
  
Name: ......................................................................... Sex (  ) F  (  ) M   Age.......     
  
Interviewer........................................ Date ....../....../......  
  
Introduction (Please read to patient)  
  
Hi, I’m __________, nice to meet you. If it’s okay with you, I’d like to ask you a few 
questions that will help me give you better medical care. The questions relate to your 
experience with alcohol, cigarettes, and other drugs. Some of the substances we’ll talk 
about are prescribed by a doctor (like pain medications). But I will only record those if you 
have taken them for reasons or in doses other than prescribed. I’ll also ask you about illicit 
or illegal drug use––but only to better diagnose and treat you.  
  
Instructions: For each substance, mark in the appropriate column. For example, if the patient has used 
cocaine monthly in the past year, put a mark in the “Monthly” column in the “illegal drug” row.  
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 If the patient says “NO” for all drugs in the Quick Screen, reinforce abstinence. 
Screening is complete.  
 If the patient says “Yes” to one or more days of heavy drinking, patient is an at-risk 
drinker.  Please see NIAAA website “How to Help Patients Who Drink Too Much: A 
Clinical Approach” 
http://pubs.niaaa.nih.gov/publications/Practitioner/CliniciansGuide2005/clinicians_gui
de.htm, for information to Assess, Advise, Assist, and Arrange help for at risk 
drinkers or patients with alcohol use disorders  
 If patient says “Yes” to use of tobacco: Any current tobacco use places a patient at 
risk.  Advise all tobacco users to quit.  For more information on smoking cessation, 
please see “Helping Smokers Quit: A Guide for Clinicians” 
http://www.ahrq.gov/clinic/tobacco/clinhlpsmksqt.htm   
 If the patient says “Yes” to use of illegal drugs or prescription drugs for non-
medical reasons, proceed to Question 1 of the NIDA-Modified ASSIST.  
                                                1  This guide is designed to assist clinicians serving adult patients in screening 
for drug use. The NIDA Quick Screen was  adapted from the single-question screen for drug use in primary care by 
Saitz et al. (available at http://archinte.amaassn.org/cgi/reprint/170/13/1155) and the National Institute on Alcohol 
Abuse and Alcoholism’s screening question on heavy drinking days (available at 
http://pubs.niaaa.nih.gov/publications/Practitioner/CliniciansGuide2005/clinicians_guide.htm).   
The NIDA-modified ASSIST was adapted from the World Health Organization (WHO) Alcohol, Smoking and 
Substance Involvement Screening Test (ASSIST), Version 3.0, developed and published by WHO (available at 
http://www.who.int/substance_abuse/ activities/assist_v3_english.pdf).   
  
Questions 1-8 of the NIDA-Modified ASSIST V2.0 
 
Instructions: Patients may fill in the following form themselves but screening personnel should offer to 
read the questions aloud in a private setting and complete the form for the patient. To preserve 
confidentiality, a protective sheet should be placed on top of the questionnaire so it will not be seen by 
other patients after it is completed but before it is filed in the medical record.  
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Question 1 of 8, NIDA-Modified ASSIST   
  
 
In your LIFETIME, which of the following substances 
have you ever used?    
*Note for Physicians: For prescription medications, please report 
nonmedical use only.  
Yes  No  
a. Cannabis (marijuana, pot, grass, hash, etc.)      
b. Cocaine (coke, crack, etc.)      
c. Prescription stimulants (Ritalin, Concerta, Dexedrine, 
Adderall, diet pills, etc.)  
    
d. Methamphetamine (speed, crystal meth, ice, etc.)      
e. Inhalants (nitrous oxide, glue, gas, paint thinner, etc.)      
f. Sedatives or sleeping pills (Valium, Serepax, Ativan, 
Xanax, Librium,Rohypnol, GHB, etc.)  
    
g. Hallucinogens (LSD, acid, mushrooms, PCP, Special K, 
ecstasy, etc.)  
    
h. Street opioids (heroin, opium, etc.)      
i.  Prescription opioids (fentanyl, oxycodone 
[OxyContin, Percocet], hydrocodone [Vicodin], 
methadone, buprenorphine, etc.)  
    
j. Other – specify:      
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 Given the patient’s response to the Quick Screen, the patient should not indicate 
“NO” for all drugs in Question 1. If they do, remind them that their answers to the 
Quick Screen indicated they used an illegal or prescription drug for nonmedical 
reasons within the past year and then repeat Question 1. If the patient indicates that 
the drug used is not listed, please mark  ‘Yes’ next to ‘Other’ and continue to 
Question 2 of the NIDA-Modified ASSIST.  
  
 If the patient says “Yes” to any of the drugs, proceed to Question 2 of the NIDA-




 For patients who report “Never” having used any drug in the past 3 months: Go to 
Questions 6-8.  
 For any recent illicit or nonmedical prescription drug use, go to Question 3.  
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3.  In the past 3 months, how often have you had a strong 
desire or urge to use (first drug, second drug, etc)?  
 
    
a.  Cannabis (marijuana, pot, grass, hash, etc.)  0  3  4  5  6  
b.  Cocaine (coke, crack, etc.)  0  3  4  5  6  
c.  Prescribed Amphetamine type stimulants (Ritalin, 
Concerta, Dexedrine, Adderall, diet pills, etc.)  
0  3  4  5  6  
d.  Methamphetamine (speed, crystal meth, ice, etc.)  0  3  4  5  6  
e.  Inhalants (nitrous oxide, glue, gas, paint thinner, etc.)  0  3  4  5  6  
f.  Sedatives or sleeping pills (Valium, Serepax, Ativan, 
Librium, Xanax, Rohypnol, GHB, etc.)  
0  3  4  5  6  
g.  Hallucinogens (LSD, acid, mushrooms, PCP, Special K, 
ecstasy, etc.)  
0  3  4  5  6  
h.  Street Opioids (heroin, opium, etc.)  0  3  4  5  6  
i.  Prescribed opioids (fentanyl, oxycodone [OxyContin, 
Percocet], hydrocodone [Vicodin], methadone, 
buprenorphine, etc.)  
0  3  4  5  6  
j.  Other – Specify:  0  3  4  5  6  
  
  
REDUCING RECIDIVISM IN ALASKA 109 
 
 
REDUCING RECIDIVISM IN ALASKA 110 
 
  
Instructions: Ask Questions 6 & 7 for all substances ever used (i.e., those endorsed in the Question 1).  
  
 
   





Instructions: Ask Question 8 if the patient endorses any drug that might be injected, including those that 
might be listed in the other category (e.g., steroids). Circle appropriate response.  
  
  
8. Have you ever used any drug by injection  No, never  Yes, but not in  Yes, in the 
past 3  
(NONMEDICAL USE ONLY)?  the past 3  months  
months  
  
 Recommend to patients reporting any prior or current intravenous drug use that they 
get tested for HIV and Hepatitis B/C.  
 If patient reports using a drug by injection in the past three months, ask about their 
pattern of injecting during this period to determine their risk levels and the best 
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course of intervention. o  If patient responds that they inject once weekly or less OR fewer 
than 3 days in a row, provide a brief intervention including a discussions of the risks associated with 
injecting.  
o  If patient responds that they inject more than once per week OR 3 or more days in a row, refer for 
further assessment.  
  
Note: Recommend to patients reporting any current use of alcohol or illicit drugs that they 
get tested for HIV and other sexually transmitted diseases.  
Tally Sheet for scoring the full NIDA-Modified ASSIST:  
 
Instructions:  For each substance (labeled a–j), add up the scores received for questions 2-7 above. This is 




 Substance Involvement Score  Total (SI SCORE) a. 
Cannabis (marijuana, pot, grass, hash,   etc.)  
b. Cocaine (coke, crack, etc.)    
c. Prescription stimulants (Ritalin,    
Concerta, Dexedrine, 
Adderall, diet pills, etc.)  
d. Methamphetamine (speed, crystal   meth, ice, etc.)  
e. Inhalants (nitrous oxide, glue, gas,  paint thinner, etc.)  
f. Sedatives or sleeping pills (Valium,    
Serepax, Xanax, Ativan, Librium,  
Rohypnol, GHB, etc.)  
g. Hallucinogens (LSD, acid, mushrooms,    
PCP, Special K, ecstasy, etc.)  
h. Street Opioids (heroin, opium, etc.)    
i. Prescription opioids (fentanyl,   oxycodone [OxyContin, Percocet], 
hydrocodone [Vicodin], methadone, buprenorphine, etc.)  
j. Other – Specify:    
  
  
Use the resultant Substance Involvement (SI) Score to identify patient’s risk level.  
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To determine patient’s Hrisk levelH based on his or her HSI scoreH, see the table below:  
  
Level of risk associated with different   
Substance Involvement Score ranges for  
Illicit or nonmedical prescription drug use  
0-3  Lower Risk  
4-26  Moderate Risk  
27+  High Risk  
  
National Institute on Drug Abuse. (2012b). Resource guide: Screening for drug use in general 
medical settings. Retrieved from https://www.drugabuse.gov/publications/resource-
guide-screening-drug-use-in-general-medical-settings/nida-quick-screen   
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Appendix H   
Patient Health Questionnaire-9 
PATIENT HEALTH QUESTIONNAIRE-9   
(PHQ-9)  
Over the last 2 weeks, how often have you been 
bothered by any of the following problems? (Use “✔” to 









1. Little interest or pleasure in doing things  0  1  2  3  
2. Feeling down, depressed, or hopeless  0  1  2  3  
3. Trouble falling or staying asleep, or sleeping too much  0  1  2  3  
4. Feeling tired or having little energy  0  1  2  3  
5. Poor appetite or overeating  0  1  2  3  
6. Feeling bad about yourself — or that you are a failure or 
have let yourself or your family down  
0  1  2  3  
7. Trouble concentrating on things, such as reading the 
newspaper or watching television  
0  1  2  3  
8. Moving or speaking so slowly that other people could 
have noticed?  Or the opposite — being so fidgety or 
restless that you have been moving around a lot more than 
usual  
0  1  2  3  
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9. Thoughts that you would be better off dead or of hurting 
yourself in some way  
0  1  2  3  
                                                                                                              FOR OFFICE CODING     0      + ______  +  ______  +  ______  
=Total Score:  ______  
          
 
If you checked off any problems, how difficult have these problems made it for you to do your work, 
take care of things at home, or get along with other people?  
Not difficult  














Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from 
Pfizer Inc.  No permission required to reproduce, translate, display or distribute. 
 
Kroenke, K., & Spitzer, R. L. (2002). The PHQ-9: A new depression diagnostic and severity 
measure. Psychiatric Annals, 32(9), 509-515. doi:10.3928/0048-5713-20020901-06  
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Appendix I   
Medication-Assisted Treatment of Opioid Use Disorder:  Pocket Guide 
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Appendix J   
Clinical Opiate Withdrawal Scale
Wesson, D. R., & Ling, W. (2003). The clinical opiate withdrawal scale (COWS). Journal of 
Psychoactive Drugs, 35(2), 253. doi:10.1080/02791072.2003.10400007
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Appendix K 
Clinical Institute Withdrawal Assessment of Alcohol Scale-Revised
 
Sullivan, J.T., Sykora, K., Schneiderman, J., Naranjo, C.A., & Sellers, E.M. (1989). Assessment 
of alcohol withdrawal: The revised Clinical Institute Withdrawal Assessment for Alcohol 
scale (CIWA-Ar). British Journal of Addiction 84:1353-1357. 
